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ABSTRACT 
Christopher N. Batuello 
Phospho-regulation and metastatic potential of Murine Double Minute 2 
 
Murine double minute (Mdm2) is a highly modified and multi-faceted protein that 
is overexpressed in numerous human malignancies. It engages in many cellular activities 
and is essential for development since deletion of mdm2 is lethal in early stages of 
embryonic development. The most studied function of Mdm2 is as a negative regulator of 
the tumor suppressor protein p53.  Mdm2 achieves this regulation by binding to p53 and 
inhibiting p53 transcriptional activity. Mdm2 also functions as an E3 ubiquitin ligase that 
signals p53 for destruction by the proteasome. Interestingly recent evidence has shown 
that Mdm2 can also function as an E3 neddylating enzyme that can conjugate the 
ubiquitin-like molecule, nedd8, to p53. This modification results in inhibition of p53 
activity, while maintaining p53 protein levels. While the signaling events that regulate 
Mdm2 E3 ubiquitin ligase activity have been extensively studied, what activates the 
neddylating activity of Mdm2 has remained elusive.  My investigations have centered on 
understanding whether tyrosine kinase signaling could activate the neddylating activity of 
Mdm2. I have shown that c-Src, a non-receptor protein tyrosine kinase that is involved in 
a variety of cellular processes, phosphorylates Mdm2 on tyrosines 281 and 302. This 
phosphorylation event increases the half-life and neddylating activity of Mdm2 resulting 
in a neddylation dependent reduction of p53 transcriptional activity. Mdm2 also has 
many p53-independent cellular functions that are beginning to be linked to its role as an 
oncogene. There is an emerging role for Mdm2 in tumor metastasis. Metastasis is a 
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process involving tumor cells migrating from a primary site to a distal site and is a major 
cause of morbidity and mortality in cancer patients. To date, the involvement of Mdm2 in 
breast cancer metastasis has only been correlative, with no in vivo model to definitively 
define a role for Mdm2. Here I have shown in vivo that Mdm2 enhances breast to lung 
metastasis through the up regulation of multiple angiogenic factors, including HIF-1 
and VEGF. Taken together my data provide novel insights into important p53-dependent 
and independent functions of Mdm2 that represent potential new avenues for therapeutic 
intervention.  
 
Lindsey D. Mayo, Ph.D., Chair 
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1. Background and Significance 
1.1 Mdm2 
 The murine double minute genes 1-3 (mdm) were identified in a transformed 
murine BALB/C cell line, as genes that were amplified greater than 50 fold (1, 2). The 
second gene product (Mdm2) was the only copy that was able to cause cellular 
transformation, leading to its characterization as an oncogene (3). Its characterization as 
an oncogene is further validated as its expression is elevated in high grade-human 
cancers. This overexpression of Mdm2 correlates with poor prognosis for patients. 
MDM2 is amplified in one-third of human sarcomas and detcted at high levels (40-90%) 
by immunohistochemistry (IHC) in tumors of the brain, breast, ovary, cervix, lung, colon, 
and prostate (4, 5).  
Murine Mdm2 protein contains 489 amino acids, whereas the human form is 491 
amino acids. Mdm2 has several conserved functional regions: the p53 binding domain in 
the amino terminus, a region containing a nuclear localization sequence and nuclear 
export signal; a central acidic domain that is essential for ubiquitination of p53 and itself; 
a zinc finger which functions in Mdm2 interactions with ribosomal proteins; and a C-
terminal RING finger domain that is required for dimer formation and ligase activity 
(Figure 1).  
The C-terminal end of Mdm2 contains a RING (Really Interesting New Gene) 
finger E3 ligase. The main purpose of this region is to mediate the attachment of 
ubiquitin to substrates. While ubiquitination is normally associated with protein 
degradation by the 26S proteasome (6), it is also involved in cellular trafficking, 
endosomal sorting, polarization of neurons, and in development (7). The process of  
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Figure 1: Schematic of Mdm2 domains 
Mdm2 contains multiple protein domains that regulate its function. The N-terminus 
contains the p53 binding domain. The central region harbors the nuclear localization and 
export sequences (NLS and NES), the acidic domain, and the zinc finger. The RING 
finger E3 ligase is found on the C-terminus of Mdm2. 
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ubiquitination starts with the activation of ubiquitin by an ubiquitin-activating enzyme 
(E1) through an ATP-dependent reaction. The activated ubiquitin is then transferred to 
the catalytic cysteine of an ubiquitin-conjugating enzyme (E2). The E2 then interacts 
with an E3 ligase to transfer ubiquitin to the lysine of a substrate. There are three types of 
E3 ligases, HECT (homologous to E6-associated protein C-terminus), RING, and U-Box, 
a modified RING motif without the full complement of Zn
2+
-binding ligands. HECT 
ligases have a direct role in transferring ubiquitin to substrates, whereas RING and U-
Box ligases act as adapter proteins that facilitate protein ubiquitination. Humans have an 
estimated eight E1 enzymes (2 for ubiquitin) (8), around 40 E2s (28 for ubiquitin)(9), and 
over 600 E3s (10). Ubiquitin modification of proteins can be either mono- or poly-
ubiquitination events and can take place through conjugation to any of the seven lysines 
or the amino terminal methionine of the ubiquitin molecule. Interestingly, specific 
linkage between ubiquitin may impart certain functions. Lysine 48 linkages are used as a 
modification for targeting proteins to the proteasome, while lysine 63 is thought to induce 
aggresome formation, lysosomal degradation, and protein-protein interactions (11).  
The oncogenic activity of Mdm2 is attributed to its ability to bind and inhibit the 
tumor suppressor protein p53. Mdm2 is able to accomplish this regulation through 
functioning as an E3 ubiquitin ligase that signals p53 for destruction by the proteasome 
(12-14). p53 plays an important role in the maintenance and integrity of the genome. 
p53’s role in cellular stress response is to function as a transcription factor, through both 
activation and repression, in a wide variety of cellular pathways including apoptosis, cell 
cycle arrest, senescence, DNA repair, and cell metabolism (15). Due to involvement of 
p53 in a multitude of cellular processes, it is highly regulated by many post-translational 
4 
modifications. p53 is modified on more than 36 amino acids as determined by various 
biochemical and cell culture studies (16).  
Interestingly one target of p53 transcriptional activity is mdm2. Due to the 
negative regulation Mdm2 has on p53, an auto-regulatory feedback loop is formed, 
whereby p53 transcriptionally activates Mdm2, which in turn degrades p53 (Figure 2). 
The ubiquitination of p53 by Mdm2 has been determined to occur on 6 C-terminal lysine 
of p53 (K370, K372, K373, K381, K382, and K386) (16). Mutation of these 6 lysines 
largely prevents degradation of p53 and modulates p53 transcriptional regulation. Mdm2 
can both mono- and poly- ubiquitinate p53 depending on Mdm2 levels. When Mdm2 
levels rise, Mdm2 promotes p53 degradation through poly-ubiquitination. Conversely, 
when Mdm2 levels are low mono-ubiquitination of p53 occurs resulting in p53 nuclear 
export (17). Another role of Mdm2 mediated ubiquitination is to prevent p53 acetylation 
by p300/CBP. The lysines required for acetylation are the same lysine residues used for 
ubiquitination. Acetylation activates p53 allowing it to bind to p53 response elements in 
the genome (18). 
The importance of Mdm2 in regulating p53 is shown by in vivo experiments in 
which mice lacking the mdm2 gene are embryonic lethal, but a viable mouse can be 
generated if both mdm2 and p53 are deleted (19, 20). Interestingly, it is the function of 
the RING finger of Mdm2 that is vital for p53 regulation during development as knock-in 
mice bearing a RING mutant (C462A) of Mdm2 still die before day E7.5 but can be 
rescued by p53 deletion (21).  
Mdm2 also functions as an E3 neddylating enzyme that conjugates the ubiquitin-
like molecule neural precursor cell expressed, developmentally down-regulated eight  
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Figure 2: The Mdm2/p53 auto-regulatory feedback-loop 
Under non-stressed conditions p53 transcriptionally activates Mdm2, which in turn 
targets p53 for degradation. This feedback loop is a primary mechanism for regulating 
p53 activity in normal cells. 
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(nedd8) to p53, which neutralizes p53 transcriptional activity (22). The nedd8 pathway 
has been demonstrated to be crucial for viability of mice, C. elegans, and S. pombe (23-
25). In addition, the mammalian cell line TS-41, which has a temperature sensitive 
mutation in the SMC gene (APP-BP1 in human) participates in multiple rounds  
of DNA replication without entering a mitotic cycle (26). Interestingly, nedd8 
conjugation has been shown to be upregulated in certain types of cancer and recently a 
general inhibitor of the nedd8 pathway, MLN4924, has been developed (27). Inhibition 
of neddylation in HCT 116 cells using MLN4924 leads to the same phenotype observed 
in the TS-41 cell line. This phenotype of re-replication is known to induce DNA damage 
and leads to apoptosis in human cancer cells and suppresses the growth of human tumors 
in mouse xenografts. 
The most well studied and first discovered substrate of nedd8 was Cdc53 in yeast 
and Cul4a in humans. Both are member of the Cullin family and are neddylated at a 
conserved lysine in their C-terminal domain. All yeast and mammalian cullins are now 
known to be neddylated. The cullin family of proteins (Cul1, 2, 3, 4A, 4B, 5, 7) serves as 
scaffolding proteins for multi-subunit ubiquitin E3 ligases. The cullins interact in their C-
terminal domain with a RING finger E3, either Rbx1 or Rbx2 and a substrate recognition 
subunit is attached to the N-terminal region (28). This entire complex is needed for an 
active ubiquitin ligase. The modification of cullins by nedd8 has been shown to increase 
the ubiquitin activity of cullin ring ligases. This increase in ubiquitination activity is due 
to a nedd8 dependent conformational change that increases Rbx binding of E2 and also 
decreases the distance between E2 and the substrate (29). The cullins are responsible for 
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the ubiquitination of numerous proteins involved in cell cycle progression and cell 
growth/survival (30).  
While the cullins are the most studied, they are not the only proteins modified by 
nedd8. Many other proteins have been shown to be neddylated. Relevant to this thesis is 
the neddylation of p53 and Mdm2. There are two E3 ligases capable of conjugating a 
nedd8 to p53, Mdm2 and FBXO11 (22, 31). Conjugation of a nedd8 molecule to p53 
inhibits its transcriptional activity. This was shown as the TS-41 cells, which have a 
temperature sensitive mutant of the Nedd8 Activating Enzyme (NAE), show higher levels 
of p53 activity when grown at the restrictive temperature (39 C). Also a fusion protein 
of p53 with a nedd8 attached to the C-terminal end resulted in lower activity as 
determined by luciferase activity from the p21 promoter (31). The sites neddylated by 
Mdm2 are lysines K370, K372, and K373 whereas FBXO11 neddylates K320 and K321 
(22). The actual mechanism of p53 transcriptional inhibition by neddylation is still under 
investigation. Unlike mono-ubiquitination of p53, which results in the movement of p53 
from the nucleus to the cytoplasm, neddylation by itself has no effect on p53 cellular 
compartmentalization (32). However expression of a nedd8 interacting protein, Nedd8 
ultimate buster 1 (NUB1), has been shown to enhance cytoplasmic p53 through an 
Mdm2/nedd8 dependent pathway (33). This mechanism cannot be fully responsible for 
inhibition though, as neddylated p53 was still detectable in the nucleus, even with 
overexpression of NUB1. Mdm2 itself has also been shown to be neddylated (22). This 
neddylation modification results in an increase in Mdm2 protein half-life. This is 
reversed when NEDP1 (a human nedd8-soecific protease) removes nedd8 from Mdm2. 
8 
Moreover, NEDP 1which can be induced by chemotherapeutics, and thus help to activate 
p53 (34).  
There are numerous splice variants of mdm2 mRNA and multiple isoforms of the 
Mdm2 protein have been identified in tumors and normal tissues (35). Two of these 
isoforms, p75 and p90, predominate in cells and migrate at 75 and 90 kDa on sodium 
dodecyl sulfate polyacrylamide gels. The 90 kDa form of Mdm2 is transcribed from the 
p53 responsive P2 promoter of Mdm2. This transcript results in a full length Mdm2 
protein capable of regulating p53. Along with p53, the P2 promoter has been shown to be 
responsive to AP-1, SP-1, and Smad3 transcription factors (11, 36, 37). The 75 kDa form 
is produced from the constitutive P1 promoter independent of p53. This 75 kDa form 
lacks the N-terminus of Mdm2 due to initiation of translation at two different internal 
AUG codons (AA 62 and 102) rendering Mdm2 incapable of binding to p53. PTEN has 
been shown to inhibit p75 Mdm2 transcription indirectly by modulating the activity of 
unknown transcription factor(38). Meanwhile, the only transcription factor that has been 
shown to induce expression from the P1 promoter is NF-κB (39). The biological 
relevance for p75 Mdm2 is currently under investigation. Interestingly mdm2 transcripts 
initiated from P1 undergo removal of exon 2 by splicing and retain exon 1; meanwhile p2 
transcripts lack exon 1, and retain exon 2 (Figure 3). 
The Mdm2 protein is highly modified by multiple site phosphorylation events that 
can alter its protein interactions, localization, stability, and its functions as an ubiquitin 
ligase. These modifications are clustered into three groups (Figure 4). The first group is 
around the nuclear localization/export signals, which are stimulated in response to growth 
factor and mitogenic signaling. The second is a group of eight sites that are found  
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Figure 3: Organization of the human mdm2 gene  
The mdm2 gene contains two unique promoters. P1 is a constitutive promoter, and P2 is 
the p53-responsive promoter. The translation start codons are indicated for each 
promoter. Initiation of translation from the P1 promoter results in an N-terminal truncated 
Mdm2 protein.  
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Figure 4: Known phosphorylation sites on Mdm2 
Phosphorylation sites are indicated by (P). Protein kinases (if known) and the effects of 
phosphorylation events are indicated. 
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between amino acids 240-269. The final group is mostly clustered at the carboxyl-
terminus and becomes phosphorylated in response to DNA damage. The phosphorylation 
sites around the bipartite NLS contain two Protein Kinase B (AKT/PKB) sites at 166 and 
186. This phosphorylation event is triggered by insulin growth factor (IGF) and results in 
the nuclear accumulation of Mdm2, which binds p53 and inhibits its transcriptional 
activity (40). In the acidic domain, T216 of murine Mdm2 has been shown to be 
phosphorylated by cyclinA/cdk. This modification results in stabilization of p53 and is 
permissive of p19ARF binding (41, 42), a negative regulator of Mdm2. Casein Kinase 2 
(CK2) phosphorylation of Mdm2 at S269 impairs Mdm2/Retinoblastoma (Rb) interaction 
and allows the binding of Mdm2 to the basal transcription factor TFII250 (43). Also 
under basal growth conditions, it has been suggested, that a group of serines located in 
the acidic domain are phosphorylated. Through use of mutation analysis it has been 
suggested that these phosphorylated serines promote Mdm2-mediated p53 turnover, 
although the kinases responsible for these events are still undefined (Figure 4). 
 Many studies have focused on Mdm2 phosphorylation in response to genotoxic 
stress. Ataxia telangiectasia mutated (ATM) has been shown to phosphorylate Mdm2 in 
response to DNA damage at S395 and block nuclear export of p53 (44). Additional ATM 
sites at S386, S425, and S428 all inhibit p53 degradation by preventing Mdm2 E3 
oligomerization (45). Ataxia telangiectasia and Rad3-related protein (ATR) 
phosphorylates Mdm2 at S407 and also prevents p53 nuclear export under certain stress 
conditions (46). An additional phosphorylation site triggered by DNA damage at serine 
17 is phosphorylated by DNA protein kinase (DNA-PK), an enzyme activated in 
12 
response to DNA double strand breaks. This phosphorylation event prevents Mdm2 
interaction with p53 in vitro and activates p53 transcriptional activity (Figure 4) (47). 
  Interestingly there are only two known tyrosine kinases for Mdm2.The first, c-
Abl, phosphorylates Mdm2 at Y394 and results in an increase of apoptosis by enhanced 
stability of p53. This increase in p53 stability is due to a c-Abl dependent promotion of 
Mdm2-Mdmx heterodimers, which enhances the degradation of both Mdm2 and Mdmx 
(48). c-Abl also phosphorylates Mdm2 at Y276 and results in enhanced p19ARF binding, 
sequestering Mdm2 from p53 (49). The other tyrosine kinase is ErbB-4. Phosphorylation 
of Mdm2 by ErbB-4 results in stabilization of p53 and increases Mdm2 ubiquitination 
(50). However the tyrosine(s) in Mdm2 have yet to be identified (Figure 4).  
 While the most studied function of Mdm2 is attributed to its regulation of p53, 
Mdm2 has been shown to engage in many p53 independent activities. Mdm2 has been 
implicated in cell cycle control, differentiation, DNA repair, basal transcription, and other 
processes. Some of Mdm2 p53-independent protein-protein interactions are detailed in 
Table 1.  
 
1.2 c-Src 
v-Src was originally isolated as the transforming agent in the Rous sarcoma virus 
(21). Its cellular counterpart c-Src is a member of the Src Family Kinase, a family of 
membrane associated non-receptor tyrosine kinases including: c-Src, c-Yes, Fyn, Lyn, 
Lck, Hck, Blk, Fgr, and Yrk. While most of the family members are expressed in the 
hematopoietic origin, c-Src shows more ubiquitous expression and is involved in many  
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Mdm2 Binding 
Partner Results of Mdm2 Binding 
p73 
Inhibits p73 transcriptional activity (does not 
degrade)(51, 52) 
p19(ARF) Blocks Mdm2/p53 binding(42) 
Rb Inhibits Mdm2-E2F1 binding(53) 
E2F1 Stabilizes E2F1 protein levels (54) 
PCAF Ubiquitinates and degrades Mdm2(55) 
JMY 
Transcriptional activator that is degraded by Mdm2 
(56) 
Histone H2B Mdm2 mono-ubiquitinates H2B  
L5 Inhibits Mdm2 ligase activity (57) 
L11 Inhibits Mdm2 ligase activity (58) 
L23 Inhibits Mdm2 ligase activity (59) 
PML Sequesters Mdm2 to nucleolus (60) 
Nbs1 
Mdm2/Nbs1 binding inhibits onset of DNA 
repair(61) 
DNA Polymerase ε 
Stimulates DNA Polymerase ε enzymatic 
activity(62) 
E-Cadherin Mdm2 ubiquitinates and degrades E-cadherin (63) 
HIF-1α Enhances HIF-1α transcriptional activity(64) 
NUMB Mdm2 ubiquitinates and degrades Numb(65) 
SCF(beta-TRCP) Ubiquitinates and degrades Mdm2(66) 
 
Table 1: Mdm2 binding partners 
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cellular processes including proliferation, survival, motility, invasiveness, and 
angiogenesis (22). 
c-Src contains an amino-terminal membrane localization sequence in the SH4 
domain that requires myristylation for localization. c-Src also contains Src homology 
domain 2 (SH2) and Src homology 3 domain (SH3) that mediate protein-protein 
interactions, a tyrosine kinase domain, and a regulatory sequence at the carboxyl-terminal 
end (Figure 4). SH3 domains generally bind to proline rich motifs with the minimal 
consensus P-x-x-P (23), while SH2 domains bind phosphorylated tyrosines (24). c-Src 
activity is regulated through phosphorylation and intra-molecular interactions. 
Phosphorylation of c-Src by C-terminal Src Kinase (CSK) at Y530 results in inactivation 
due to intermolecular binding between phosphorylated Y530 and the SH2 domain, 
resulting in a “closed” conformation of the protein (25, 26) (Figure 5). The v-Src protein 
has a C-terminal deletion resulting in loss of inhibitory phosphorylation on Y530.  
Activation of c-Src can result from dephosphorylation of the Y530 by a protein 
phosphatase. Protein tyrosine phosphatase (PTP)-alpha, PTP1, PTP1B, and SH2-
containing protein tyrosine phosphatase-1 (SHP-1) have all been implicated in c-Src 
activation (27, 28). c-Src activity can be augmented by higher intermolecular binding of 
the SH2 and SH3 between cellular ligands, such as platelet-derived growth factor 
receptor (PDGFR) or focal adhesion kinase (1) (29, 30). This activation of c-Src results in 
its open conformation with greater access to the SH2 and SH3 binding domains. For full 
activation, c-Src must undergo auto-phosphorylation at Y419 in its catalytic domain.  
c-Src is rarely mutated in human cancers. Only a small set of colon cancer 
patients have been found to have an activating mutation similar to v-Src. Elevated levels  
15 
 
 
Figure 5: Structure and activation of c-Src 
c-Src contains four homologous domains. The SH4 contains a myristoylation sequence 
and supports plasma membrane binding. The SH3 domain is a proline rich sequence that 
binds and interacts with other proteins. The SH2 domain recognizes phosphorylated 
tyrosine residues and regulates binding to other proteins. The SH3 and SH2 domains also 
function in intra-molecular interactions. The Y419 is located in the kinase domain and is 
auto-phosphorylated during activation. c-Src activation is regulated by the 
phosphorylation status of Y530. When phosphorylated, c-Src is in an inactive 
conformation due to p-Y530 binding to the internal SH2 domain. When 
dephosphorylated the conformation of c-Src opens allowing for activation.  
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of c-Src protein or an increase in activity are more commonly observed in human 
cancers. This is seen in cancers of the lung, breast, colon, and skin (67-69). Even though  
c-Src is involved in multiple pathways important for tumorigenesis and is seen at 
elevated levels in human cancers, c-Src itself is not a strong transforming oncogene (70). 
This has led to the hypothesis that c-Src can help facilitate the oncogenic roles of other 
proteins rather than being a strong autonomous transforming agent. To aid in 
tumorigenesis c-Src interacts with numerous tyrosine receptor kinases and other proteins 
implemented in cancer progression including PDGFR, vascular endothelial growth factor 
(VEGFR), epidermal growth factor receptor (EGFR), human epidermal growth factor 
receptor 2 (HER2), human epidermal growth factor receptor 3 (HER3), signal transducer 
and activator of transcription (STATs), heteromeric G proteins, cyclin D and E, and FAK 
(71). This diverse list shows c-Src integration in numerous cellular processes and how 
many different pathways c-Src may augment for cancer development.  
 
1.3 Cancer Metastasis 
Metastasis is a multi-staged process that cancerous cells undergo to relocate from 
their primary location to a distant site. Metastasis usually correlates with a poor prognosis 
and often results in death due to lack of treatment options. For metastasis to occur, tumor 
cells must first invade into the surrounding tissue of the primary site. This is followed by 
entrance into the circulation system, either through the lymph nodes or blood, where the 
tumor cell must survive until it can find a distal site suitable for growth (Figure 6).  
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Figure 6: The tumor metastatic process 
Metastasis of a tumor to a distal tissue involves a three-step process: First, tumor cells 
must be able to leave the primary tumor site and invade the vasculature. Second, they 
must survive in the bloodstream until they can arrest and extravasate into surrounding 
tissue. Finally they must interact with the microenvironment to establish metastatic 
colonization.  
 
18 
For a tumor cell to enter into the primary site around the tissue, it must lose 
contact from its surrounding cells and to the extra-cellular matrix. The contacts between 
cells are usually mediated by the cell attachment proteins of the cadherin family, which 
bind cells together through their extracellular domains (72). Loss of E-cadherin is a 
hallmark of epithelial-mesenchymal transition (EMT), which is defined by loss of 
epithelial characteristics including apical-basal polarity, tight junctions, expression of E-
cadherin, and decreased cell mobility. The loss of these characteristics are combined with 
the gain of mesenchymal phenotype markers such as increases in vimentin and myosin 
expression, loss of polarity, and an increase in cellular mobility (73). Tumor cells are 
bound to the extra cellular matrix (ECM) through heterodimers of one alpha and one beta 
integrin protein. The alpha family consists of 18 members while the beta has 8. Each 
heterodimer binds to a specific protein of the ECM (74). For a tumor cell to begin to 
invade into surrounding tissues it must release its attachment to cells and ECM. This is 
accomplished through the use of proteases that degrade the ECM and attachments. The 
family of matrixmetalloproteinases (MMPs) is responsible for the breakdown of 
extracellular matrix. MMPs are normally secreted in an inactive form and are activated 
upon cleavage by extracellular enzymes (75).  
 Tumors first need to recruit a blood supply to aid in the metastatic process. The 
formation of new blood vessels from pre-existing ones is termed angiogenesis. 
Angiogenesis is required in order to support the growth and survival of tumors by 
delivering oxygen and other nutrients and metabolites to the tumor cells (76). 
Angiogenesis is simulated by pro-angiogenic factors that must counteract anti-angiogenic 
factors. Thus, the angiogenic switch will commence when the pro-angiogenic factors 
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outnumber the inhibitors. Important to this thesis are the roles of the pro-angiogenic 
molecule vascular endothelial growth factor (VEGF) and the anti-angiogenic molecule 
Maspin. The VEGF and the VEGF receptor (VEGF-R) pathway is one of the most 
studied pro-angiogenic factors. Multiple signaling networks are activated in response to 
VEGF/VEGF-R signaling and result in endothelial cell survival, mitogenesis, migration, 
and differentiation. VEGF also increases vascular permeability and initiates the 
mobilization of endothelial progenitor cells from the bone marrow into the peripheral 
circulation. The permeability induced by VEGF leads to access for the pro-angiogenic 
factors to enter the vessels and facilitate angiogenesis. VEGF activates its angiogenic 
switch through binding to one of three VEGF receptors. VEGF-R1 is responsible for 
most physiologic and developmental neo-vascularization (77). VEGF-R2, meanwhile, 
mediates the majority of the downstream effects of VEGF in angiogenesis, including 
microvascular permeability, endothelial cell proliferation, invasion, migration, and 
survival (78). VEGF-R3 is a receptor tyrosine kinase that is expressed mainly during 
development in the embryonic vasculature but is only expressed in lymphatic endothelial 
cells in adults (79). Due to its role in numerous cancers and angiogenesis, the 
VEGF/VEGFR pathway has been targeted clinically with drugs that inhibit both VEGF 
and VEGF-R.  
 Due to the prominent role VEGF plays in angiogenesis, understanding VEGF 
regulation is very important. VEGF is regulated in numerous ways including by 
oncogenes/tumor suppressor, transcription factors, and environmental factors. Important 
for this thesis is the regulation of VEGF by decreases in oxygen concentration, termed 
hypoxia, and the transcription factor hypoxia inducible factor 1-alpha (HIF-1α). In 
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response to hypoxic conditions, cells must adapt by changing metabolic, bioenergetic, 
and redox demands for oxygen. To support these changes, cells must lower demands for 
growth, conserve energy, and induce survival and pro-angiogenic factors. While many 
pathways regulate the hypoxic response, including mammalian target of rapamycin 
(mTOR) and the unfolded protein response, the main transcription factor to mediate a 
transcriptional response to hypoxic conditions is HIF-1 α. The transcriptional response 
driven by HIF-1α is dependent on its ability to bind canonical DNA sequences, called 
hypoxia response elements (HRE), in the promoter of target genes. HIF-1α is a member 
of the bHLH-PAS family of transcription factors. The active transcription factor consists 
of a dimer combining a HIF-α and HIF-β subunit. The regulation of the HIF transcription 
factor resides in the stability of the α-subunit, of which 3 are known. The α-subunit is 
constitutively expressed but in the presence of oxygen the α-subunit is ubiquitinated and 
degraded by the von Hippel Lindau (VHL) protein through the 26S proteasome. This 
degradation takes place due to hydroxylation of HIF-1α under normal oxygen conditions. 
These hydroxylation events, performed by specific prolyl hydroxylases (PHD), occur on 
proline 402 and 564 in the oxygen dependent degradation domain of HIF-1α (80). These 
proline modifications allow for the binding of VHL, which serves as the substrate 
recognition component of an E3 ubiquitin ligase complex (Figure 7) (81). Under oxygen 
deprivation, the proline hydroxylases are inactive resulting in a stabilization of the HIF-
1α subunit. Once stabilized HIF-1α subunits travel to the nucleus and dimerize with the 
HIF-β subunits and transcribe at least 150 genes that regulate cell metabolism, survival, 
motility, basement membrane integrity, angiogenesis, hematopoiesis, and other cellular 
functions (Figure 6) (82). 
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Figure 7: HIF-1α/VHL pathway 
Under normoxic conditions HIF-1α is hydroxylated on proline 402 and 564 by prolyl-
hydroxylases (PHD). This allows for the binding of VHL which ubiquitinates and 
degrades HIF-1α. Under hypoxic conditions, PHD’s are not active resulting in stable 
HIF-1α, which can interact with HIF-1β and activate hypoxic response genes. 
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One anti-angiogenic factor counteracting VEGF is the p53 induced tumor 
suppressor Maspin. The maspin gene was discovered by subtractive hybridization by its 
expression of mRNA in normal but not tumor-derived mammary epithelial cells (83). It 
has been classified as a member of the serpin protease inhibitors family and further 
defined as a member of the ov-serpin subfamily. This subfamily consists of thirteen 
members, including plasminiogen activator inhibitor 1 and 2, which are involved in 
angiogenesis, apoptosis, and embryogenesis. All ov-serpin proteins have serine protease 
inhibitor function, except for maspin (84). This inhibition is accomplished through a 
conformational change in the serpin reactive site loop (RSL) upon binding to the protease 
resulting in a covalent bond between the RSL and the catalytic site of the protease. 
Maspin however does not appear to be a protease inhibitor. Maspin RSL is not conserved 
and is shorter than all other family members and does not undergo conformational 
changes (85). Interestingly, maspin is the only ov-serpin whose deficiency is embryonic 
lethal in mice (86).  
 The tumor suppressor functions of Maspin are attributed to its roles in cell 
migration/invasion, angiogenesis, and apoptosis (87-89). For angiogenesis to occur, 
vessel endothelial cells must be activated by factors (such as VEGF) that allow it to 
escape from the vessel walls. Once free, these endothelial cells can participate in the 
formation of new vasculature in tumors. Cell adhesion and migration regulate the release 
of endothelial cells from the original vessel. Maspin regulates this process by increasing 
endothelial adhesion to fibronectin, lamin, and collagen. This binding is increased 
through upregulation of integrin-linked kinase (90) and FAK signal transduction 
pathways that regulate attachment and focal adhesion disassembly (87). This prevents the 
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release and migration of endothelial cells from established vasculature. This is validated 
in vivo as treatment with recombinant Maspin resulted in a loss of vessel formation, as 
determined by CD31 staining, in tumors of nude mice. Also, Maspin effectively blocked 
neovascularization mediated by basic fibroblast growth factor (bFGF) in rat corneas (91). 
For its role in apoptosis, maspin mainly functions through the down-regulation of the 
anti-apoptotic protein Bcl-2, although the exact mechanism is still unknown. This 
downregulation of Bcl-2 allows Bax, an apoptotic inducing protein, to become active thus 
increasing mitochondria membrane permeability (92, 93). 
 Once angiogenesis has taken place and the tumor cells are able to access the 
vasculature, they must be able to survive in this new environment. This survival requires 
evading immune cells and avoiding anoikis, cell death due to detachment from a 
substratum. Beyond survival, tumor cells must at some point stop circulating (arrest) to 
allow them to escape from the vessels. Arrest is mediated by tumor cells through 
regulation of their own integrins and also by binding to coagulation factors (94, 95). It 
has been proposed that vessel endothelial cell selectin molecules may also aid in tumor 
cell arrest (96). Also, some cancer cells arrest due to size restriction of the capillaries.  
 The final stage of metastasis involves the colonization of a distal site. 
Interestingly, most cancers show a predisposition to metastasize to certain organs. This 
observation has led researchers to search for genes that identify specific organ metastasis 
(97). One example is the multitude of work that has been done on the requirements for 
breast cancer to bone metastasis. Breast cancer cells form osteolytic metastases through 
the regulation of osteoclast activating factors parathyroid hormone-related protein 
(PTHRP), interleukin (IL)-11, IL-6, tumor necrosis factor (TNF)-α, granulocyte-
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macrophage colony-stimulating factor (GM-CSF), and receptor activator of nuclear factor 
kappa-B ligand (RANK-L). These factors are essential for the growth of osteolytic 
lesions in the bone environment, but would offer no advantage to another metastatic site 
or the tumor (98). Interestingly, c-Src has also been implicated in breast to bone 
metastasis through its regulation of bone remodeling. c-Src knockout mice develop 
osteopetrosis due to deficiency in bone remodeling (99). Mice injected with MDA-231 
breast cancer cells overexpressing c-Src have more osteolytic bone metastases than 
control mice, linking c-Src to bone colonization (100).  
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2. Materials & Methods 
2.1 Cell Culture  
All mammalian cells were cultured at 37 °C in a humidified incubator with 5% 
CO2 in Dulbecco's modiﬁed Eagle's medium (DMEM) high glucose supplemented with 
10% fetal bovine serum and penicillin-streptomycin solution. shGPF and shMdm2 TMD-
231 cells were kept under constant selection with puromycin (2 g/ml).  
 
2.2 Transfection 
Cells were transfected using the calcium phosphate method or Lipofectamine 
(Invitrogen). For calcium phosphate method plasmid DNA (1-5 µg), water (130 µl), and 
2M CaCl2 (17 µl) where mixed to a total volume of 150 l. This mixture was then added 
dropwise to 150 l of 2X HBS (275 mM NaCl, 1.5 mM Na2HPO4, 50 mM HEPES, pH 
7.0) while vortexing. Solution was incubated for 30 min at RT before adding dropwise to 
cells. This (300 l) amount is used for an individual well of a 6 well plate. For 10 cm 
dishes volumes are raised to 500 l each, for a total of 1 ml transfection reagent. DNA 
concentration was also raised to 5 µg. Lipofectamine transfections were done according 
to manufacturer’s protocol.  
 
2.3 Generation of shGFP and shMdm2 TMD-231 cell lines  
Retroviruses encoding shRNA to GFP and Mdm2 (pLKO.1 vector) were 
packaged in 293T cells together with second-generation packaging constructs, pCMV-
dR8.74 and pMD2G. Supernatant media containing virus were collected at 36 to 48 
hours, supplemented with 4 μg/mL polybrene, filtered through a 0.45-μm filter, and 
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added to cells overnight. Uninfected cells were removed by selection with puromycin (2 
μg/mL). 
 
2.4 Luciferase Assays 
For the luciferase assays, H1299 and MCF7 cells were transfected with PG13-
Luc, Mdm2-P2-Luc, Maspin-Luc, Mutant Maspin-Luc (MT1) or HRE-Luc along with 
Myc-LacZ for determination of β-galactosidase activity, using the calcium phosphate 
method. Reporter activity was normalized to β-galactosidase activity. Data generated 
were done in triplicate and standard deviation was calculated from the mean.  
 
2.5 Glutathione S-Transferase-pull down assay 
GST-SH3-Src and GST alone for control were incubated with glutathione-
sepharose beads that had been pre-washed in TEN100 Buffer (20 mM Tris, pH 7.4, 0.1 
MmM EDTA and 100 mM NaCl) for1 hr at 4 C. After GST-proteins were immobilized 
the complexes were spun down and washed four times for 15 min each with TEN100. 
After washing, recombinant His-Mdm2 was incubated with immobilized GST-SH3-Src 
or GST for 1 hr at 4 C. After complexes formed, they were spun down and were washed 
four times in NTEN Buffer (.5%NP40, 1 mM EDTA, 20 mM Tris, pH 7.4, 1 M NaCl). 
The bound proteins were eluted in SDS-Loading Buffer and western blot analysis was 
performed. 
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2.6 Cloning of Mdm2 mutants  
2.6.1 Wild-Type Mdm2 
Wild-type Mdm2 was subcloned from a pCDNA 3.1 expression plasmid into the 
pRSETA vector for protein purification using BamHI and PstI restriction enzyme sites 
(Figure 8). 
 
2.6.2 Mdm2 90-383 
90-383 deletion mutant of Mdm2 was cloned using two internal HindIII site in 
wild-type Mdm2. The 90-383 piece liberated from WT Mdm2 was cloned into the 
pRSETA vector for protein purification using the HindIII site. Sequence analysis was 
performed to ensure proper orientation, as this was a non-directional cloning procedure 
(Figure 8).  
 
2.6.3 Mdm2 4-268 
The 4-268 deletion mutant of Mdm2 was sub-cloned from the PGEX 4T3 vector 
using EcoRI and subcloned into the pRSETB vector using the same site. Sequence 
analysis was performed to ensure proper orientation, as this was a non-directional cloning 
procedure (Figure 8). 
 
2.6.4 Mdm2 102-491 
The 102-491 deletion mutant of Mdm2 was generated by PCR amplification. The 
DNA fragment was cloned into pRSETA for protein purification using BamHI and PstI 
restriction sites (Figure 8). 
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Figure 8: Restriction sites used for cloning of Mdm2 truncation mutants 
All mutants were cloned in the designated pRSET vector for protein purification. HA 
represents a human influenza hemagglutinin tag. 
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2.7 His-ubiquitn and His-Nedd8 pulldowns 
H1299 cells were transfected with His-ubiquitin or His-nedd8 and other plasmids 
using calcium phosphate method. Forty-eight hr after transfection cells were lysed in 1 ml 
of 6 M guanidinium–HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris–HCl pH 8.0 plus 5 
mM imidazole and 10 mM -mercaptoethanol. After sonication, the lysates were mixed 
with 30 l of Ni2+-NTA-agarose beads (Qiagen) prewashed with lysis buffer and 
incubated for 2 hr at room temperature. The beads were successively washed for 15 min 
in each of the following: 6 M guanidinium–HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M 
Tris–HCl pH 8.0 plus 10 mM -mercaptoethanol; 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 
0.01 M Tris–HCl pH 8.0, 10 mM -mercaptoethanol; 8 M urea, 0.1 M 
Na2HPO4/NaH2PO4, 0.01 M Tris–HCl pH 6.3, 10 mM -mercaptoethanol (Buffer A) plus 
0.2% Triton X-100; buffer A and then buffer A plus 0.1% Triton X-100. After the last 
wash with buffer A the beads were eluted with 200 mM imidazole in 5% SDS, 0.15 M 
Tris–HCl pH 6.7, 30% glycerol, 0.72 M -mercaptoethanol. Elutes were subjected to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) and western 
blotting. 
 
2.8 Purification of recombinant proteins  
For purification of His-tagged proteins a 50 ml culture of BL-21 Escherichia coli 
was grown overnight at 37 C at 25,000 rpm. On the day of purification the culture was 
reseeded in 200 ml of Lysogeny broth (LB) to a 0.1 optical density (OD) value. The 
bacteria were allowed to grow to 0.6 OD before the induction with 100 mM of Isopropyl-
β-D-thio-galactoside (IPTG). Induction was performed at 24 C for four hr. After 
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induction cells were spun down at 6000 rpm for 10 min and resupsended in Buffer A (25  
mM Hepes, 0.2% TX-100, 5 mM DTT, 1 M KCL) and sonicated 4 times for 30 sec on 
ice. After centrifugation at 10,000 rpm for 25 min at 4 C, the supernatant was removed 
and 40 l of pre-washed (Buffer A) Ni-NTA slurry (Qiagen) was added. Binding was 
allowed to occur for 30 min at 4 C. Complexes were spun down at 1500 rpm for 5 min 
and then washed six times for 15 min in Buffer B (Buffer A+10 mM imidazole). Proteins 
were then for eluted in Buffer C (Buffer A+300 mM imidazole) and dialyzed into 
Dialysis Buffer (50 mM HEPES pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM DTT). 
 
2.9 In vitro kinase reactions 
Src and Abl kinase reactions were performed at 37 °C for 30 min in kinase buffer 
(25 mM Tris, pH 7.4, 10 mM MgCl2, 1 mM MnCl2, 0.5 mM DTT, 10 μM ATP) using 0.1 
μg of Src (Calbiochem) or Abl (Invitrogen). 
 
2.10 In vitro ubiquitination reactions 
For in vitro ubiquitination assays; 500 ng of p53 was incubated with 50 ng E1 
(Boston Biochem), 200 ng Ubch5a (Boston Biochem), and 1 g ubiquitin (Boston 
Biochem) in the presence of 500 ng phosphorylated or unphosphorylated Mdm2. 
Reactions were performed for 2 hr at 37 C. 
 
2.11 Protein analysis, immunoprecipitation, and Western blotting 
Whole cell extracts lysates were prepared in Nonidet P-40 lysis buffer (25 mM 
Tris, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1% Nonidet P-40, 1 mM 
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sodium orthovanadate, 1 mM dithiothreitol (DTT)) and supplemented with protease 
inhibitor mixture set III (Calbiochem) at 1:100 and incubated on ice for 30 min. Debris 
was collected by centrifugation, and supernatant collected. Protein concentration was 
determined using Bradford assay. For immunoprecipitation assays 500 µg of lysates were 
incubated over night with antibody at 4 °C in 700 μl of PBS. 20 l of pre-washed Protein 
A/G Plus Agaraose (Santa Cruz Biotechnology) was added to the mixture and incubated 
an additional 4 hr at 4 °C, precipitates were washed three times in PBS, and samples were 
resuspended in SDS loading buffer.  
 
2.12 Cell cycle analysis 
TMD-231 shGFP or shMdm2 cells were serum starved for 24 hr. After serum 
starvation, cells were given 1% serum for 0, 8 and 24 hr. Cells were then harvested and 
resuspended in 1.2 mL of PBS. 3 mL of 100% ethanol was then added dropwise to cells, 
while vortexing. The cells were then fixed in this 70% ethanol solution for 30 min. After 
fixing, cells were spun at 2200 rpm for 10 min and washed twice in 15 mL of PBS. 
Pellets were resuspened in 4.5 mL of PBS and 0.5 mL RNase stock (1 mg Rnase/1 mL 
H2O) and incubated for 30 min at 37º C. After incubation cells were washed twice in PBS 
and resuspened in 2 mL propidium iodide (PI) stain solution (10 mg PI/100 mL PBS) at a 
final concentration of 1x^
6
 cells/mL. The cells were analyzed on a flow cytometer. 
ModFit analysis determined the percentage of cells in a specific stage of the cell cycle. 
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2.13 Plating Efficiency  
TMD-231 shGFP and shMdm2 cells were counted and plated from a single cell 
suspension for clonogenic survival. Cells grew for 14-21 days at 37°C. Cells were then 
fixed with a 3:1 methanol/acetic acid mixture and stained with crystal violet. Colonies 
with ≥50 cells were included in the survival analysis. Plating efficiency (PE) was 
determined by number of colonies counted divided by number of cells plated.  
 
2.14 Cell Attachment Assay 
Six-well plates were coated with 5 μg/ml fibronectin at 37 °C for 1 hr, washed 
twice with PBS, and then incubated with 1% bovine serum albumin at 37 °C for 1 hr. 
Plates were then washed twice with PBS. 2x10
^4
 TMD-231 shGFP or shMdm2 cells were 
plated with 2 ml of culture medium per well and incubated in the 37 °C, incubator for 30 
min. The culture medium was removed and cells were washed twice with PBS, 
trypsinized and counted on a Beckman Coulter Cell Analyzer.  
 
2.15 Matrigel Invasion Assay 
 2.5x10
^4
 cells were seeded in into each well of matrigel chambers. 5% serum was 
used as the chemoattractant. The chambers were incubated for 22 hr in a humidified 
tissue culture incubator, at 37º C, 5% CO2. After incubation the media was removed and 
the surface of the membrane was scrubbed using a cotton tip swab, to ensure removal of 
non-invading cells. After scrubbing, the membranes were removed from the chambers 
and stained in methanol for 2 min followed by 1% toludine blue for 2 min. The chambers 
were counted at magnification of 20X. Multiple fields for each set were counted and the 
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experiment was done in triplicate. Percent invasion was calculated using the following 
equation.  
 
 
2.16 Assessment of tumorigenicity in vivo 
The Indiana University In Vivo Therapeutics Core was responsible for all animal 
work. 7.5x10
^5
 cells of either TMD-231 shGFP or ShMdm2 cells were injected into the 
mammary fat pad of γ-null NOD-SCID mice (n=10 per group). All mice developed 
tumors. Tumor growth was calculated by volumetric analysis using calipers. The tumors 
were allowed to grow to an average volume of 600 mm.  
 
2.17 Tissue preparation and staining 
 The Indiana University Pathology Core performed all tumor preparation and 
staining for hematoxylin & eosin (H&E) and CD31. 
 
2.18 Lung metastasis evaluation 
 The right and left lobe of the lungs from each mouse was stained with H&E and 
mounted on a slide. The entire lung of each mouse was scored for metastases. A 
metastatic legion was defined as ≥5 tumor cells.  
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 3. c-Src phosphorylates and switches Mdm2 to a neddylating enzyme 
3.1 Introduction 
As previously described, c-Src is one of the 9 members of the Src-family kinases. 
It is a cytoplasmic non-receptor tyrosine kinase that is a critical initiation site for multiple 
signal transduction pathways and interactions. 
One of the downstream effectors of c-Src is the survival factor Akt. Akt has been 
shown to phosphorylate many substrates to promote cell survival including Mdm2 (40, 
101). Mdm2 undergoes nuclear translocation in response to Akt phosphorylation at serine 
166 and 186 (40). Once in the nucleus Mdm2 binds to the tumor suppressor p53 and 
inhibits its transcriptional activity along with functioning as an E3 ubiquitin ligase to 
signal nuclear export and proteasomal degradation. While normally kept at low levels, 
p53 is stabilized through post-translational modifications to both itself and Mdm2 in 
response to genotoxic stress (102). While the ubiquitin ligase activity of Mdm2 is 
important for regulating p53 activity, other mechanisms are currently under investigation. 
Interestingly Mdm2 can regulate p53 function by conjugation of nedd8. This 
modification results in a transcriptionally inactive p53 but what regulates Mdm2 
neddylating activity is still unknown (22).  
In the tumor microenvironment there are numerous growth factors and cytokines 
secreted from various invading cells and the stroma. This signaling leads to p53 levels 
that are generally not lower but elevated. This suggests that the Mdm2-mediated 
destabilization of p53 was not functional. Here we examined if Mdm2 neddylation 
activity could be regulated in response to growth factor activated signaling cascades. 
Here we show a novel Mdm2/c-Src interaction that results in the phosphorylation of 
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Mdm2 at Y281 and Y302. These phosphorylation sites are distinct from the previously 
reported sites for c-Abl. This novel phosphorylation event increases the half-life of 
Mdm2. Analysis of the enzymatic activity of Mdm2 shows that Mdm2 is unable to be 
loaded with ubiquitin and thus did not conjugate ubiquitin to p53. In contrast, Src-
phorphorylated Mdm2 resulted in loading of nedd8 to itself and to p53. This switch of 
Mdm2 enzymatic activity results in inactive but elevated levels of p53. This Src-mediated 
activation of the neddylating activity of Mdm2 provides a mechanism for inactive-stable 
p53 in cultured cells and tumor cells. 
 
3.2 Results 
Mdm2 is a substrate for the non-receptor kinase c-Abl under genotoxic stress 
conditions (103). c-Abl contains an SH3 domain, which binds to partner proteins 
containing an SH3 binding domain (P-x-x-P). Mdm2 contains two SH3 P-x-x-P binding 
domains, so we investigated whether Mdm2 could bind to other tyrosine kinases that 
have an SH3 domain. Recombinant Mdm2 was incubated on a SH3 domain array from 
Panomics. Mdm2 bound to c-Abl, Abl2, c-Src and Hck-specific SH3 domains (Table 2). 
Due to the prominent role of c-Src in tumorigenesis, we pursued this interaction 
with Mdm2 further. To define specific Mdm2 domains required for SH3-Src binding, a 
series of His-tagged recombinant Mdm2 truncation mutants were made (Figure 9A). 
These Mdm2 mutants were incubated in a GST-pulldown assay with either GST or the 
GST-SH3 domain of Src (SH3-Src). All Mdm2 mutants bound the SH3-Src domain, but 
not by GST alone, revealing the portion of Mdm2 needed for the Src interaction is 
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Table 2: SH3 domain array 
Recombinant Mdm2 was incubated with an SH3 domain array (Panomics) containing 
SH3 domains of indicated proteins. Unbound Mdm2 was washed away and western 
analysis performed for Mdm2. (+) indicates a positive interaction.  
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Figure 9: c-Src binds Mdm2 between aa90-268 
(A) Schematic of recombinant Mdm2 truncation mutants. (B) Western blot analysis of 
GST and Mdm2. GST-pulldown assay was done using recombinant GST or GST-SH3-
Src and recombinant Mdm2 proteins.  
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between residues 102-268 (Figure 9B). This is a region that contains an SH3 binding 
domain. To further validate this interaction and determine if it would occur in vivo, an 
immunoprecipitation of endogenous Src from MCF7 cells was performed and shows that 
Mdm2 and c-Src are in a complex (Figure 10).  
Since our data indicate that the non-receptor tyrosine kinase c-Src interacts with 
Mdm2, we hypothesized that Mdm2 could be a substrate for tyrosine phosphorylation by 
c-Src. Mdm2 is a highly phosphorylated protein and yet only two tyrosine kinases have 
been identified to phosphorylate Mdm2 (49, 50, 103). The Mdm2 protein has 14 tyrosines 
residues, 3 of which are already identified as c-Abl sites (Figure 11). To determine if c-
Src could phosphorylate Mdm2 an in vitro kinase reaction was performed using 
32
P γ-
labeled ATP. Mdm2 was incubated alone, with c-Src or with c-Abl as a positive control. 
As expected, Mdm2 was phosphorylated by c-Abl. Interestingly c-Src also 
phosphorylated Mdm2, providing evidence that Mdm2 is a substrate for Src. (Figure 12).  
To determine which tyrosine(s) is targeted for phosphorylation by c-Src another 
in vitro kinase reaction was performed using the Mdm2 truncation mutants (Figure 9A). 
The different mutants were incubated with c-Src and then immunoblot analysis was 
performed using an anti-phosphotyrosine antibody (4G10). The blot was then stripped 
and re-probed for Mdm2 (SMP14). Comparison of the blots revealed that the WT, 102-
491, and 90-383 were all effectively phosphorylated by c-Src (Figure 13A.). However, 
the Mdm2 truncation mutant 4-268 was unable to be phosphorylated by c-Src as shown 
by the outline squares (Figure 13A). Of note the 4-268 mutant of Mdm2 still contains a 
SH3 binding domain and was able to bind to SH3-Src, thereby eliminating the possibility 
that the loss of tyrosine phosphorylation was a result of Src not binding to Mdm2. Thus,  
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Figure 10: Mdm2 and c-Src interact in vivo 
Western blot of immunoprecipitation of endogenous c-Src from MCF7 cell extracts was 
followed by western blot analysis of c-Src and Mdm2. 
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Figure 11: Schematic of tyrosines in Mdm2 
Mdm2 contains 14 tyrosines. There are three known c-Abl phosphorylation sites (P) in 
Mdm2. 
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Figure 12: c-Src phosphorylates Mdm2 in vitro 
Autoradiograph of 
32
P incorporation in an in vitro kinase reaction of Mdm2 (p-Mdm2) by 
c-Src. c-Abl phosphorylation of Mdm2 and c-Abl/c-Src autophosphorylation were used 
as positive control.  
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Figure 13: c-Src phosphorylates Mdm2 at Y281 and Y302 
(A) Western blot analysis of Mdm2 and phospho-tyrosine (pTyr) of in vitro 
phosphorylation reaction on truncated Mdm2 proteins. Square outline highlights the 
inability of truncation mutant 4-268 to be phosphorylated by c-Src. (B) Tyrosine to 
phenylalanine mutants to each site Y281F and Y302F or in combination, Y281-302F, 
were generated in the 90-383 Mdm2 background. In vitro kinase reaction was performed 
with c-Src using Mdm2 point mutants followed by western blotting as performed in (A). 
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the in vitro kinase reaction narrowed down the potential c-Src phosphorylation site(s) to 
amino acids 268-393, which incorporates Y276, Y281, and Y302. Since c-Src and c-Abl 
are predicted to have different recognition sequences (104) and Y276 is already a known 
c-Abl phosphorylation site, this left Y281 and Y302 as potential c-Src phosphorylation 
sites. To establish which site is necessary for c-Src phosphorylation, site-directed 
mutagenesis was performed. Y281F, Y302F, and anY281-302F double mutant were 
created in the 90-383 truncated form of Mdm2. The mutants were used as substrates for 
an in vitro kinase reaction with c-Src. As shown in Figure 13B, the Y281-302F mutant 
was not phosphorylated by c-Src, while the single mutants were phosphorylated.  
Since we mapped the phosphorylation sites on Mdm2 to Y281 and Y302, it was 
necessary to determine if Mdm2 could be a substrate in vivo. This was tested by two 
approaches. First, H1299 cells were transfected with HA-tagged Mdm2 (HA-Mdm2) with 
either constitutively active c-Src (CA-Src) or a kinase dead Src (KD-Src). The CA-Src 
has a point mutation, Y530F, that prevents the normal down regulation of kinase activity 
and the KD-Src has a point mutation, K297R, which results in catalytically inactive c-
Src. An immunoprecipitation was then performed using the HA-tag followed by 
immunoblot analysis using anti-phosphotyrosine antibody (4G10). Tyrosine 
phosphorylation of Mdm2 was observed in the presence of CA-Src, but not KD-Src 
(Figure 14A). Along with overexpression, it was crucial to determine if c-Src could 
phosphorylate endogenous Mdm2. For this second approach pharmacologic inhibition of 
c-Src was used. MCF7 cells were pretreated with the c-Src selective inhibitor PP1 for 16 
hr followed by immunoprecipitation with Mdm2. Immunoblot analysis for 
phosphorylated tyrosine revealed that c-Src inhibition resulted in a loss of endogenous  
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Figure 14: Mdm2 is phosphorylated by c-Src in vivo 
(A) Immunoprecipitation of HA-tag from transient transfections of H1299 cells with HA-
Mdm2, KD-Src, or CA-Src. Immunoprecipitation was followed by western blot of p-Tyr 
and HA. Western analyses of lysate show c-Src expression. (B) Western blot of Mdm2 
and p-Tyr. Mdm2 was immunoprecipitated from MCF7 extracts after treatment with 10 
μM of the c-Src inhibitor PP1 for 16 hr.  
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Mdm2 tyrosine phosphorylation (Figure 14B). Mdm2 levels were observed after the 
immunoblot was re-probed for Mdm2. Thus, our in vitro and in vivo data shows that 
Mdm2 is a substrate for c-Src. 
Since we have previously shown that Mdm2 is rapidly degraded following DNA 
damage induced c-Abl phosphorylation (48), we examined the possibility that c-Src 
phosphorylation would also decrease the levels of Mdm2. H1299 cells were transfected 
with Mdm2, Mdm2 + CA-Src, or Mdm2 + KD-Src. Conversely, western blot analysis 
showed an induction of Mdm2 protein levels in the presence of CA-Src, but not in the 
presence of KD-Src (Figure 15A). To examine if an increase in c-Src activity would 
result in a dose-dependent increase in Mdm2 protein levels, H1299 cells were transfected 
with Mdm2 and with increasing concentrations of CA-Src. As expected, Mdm2 protein 
levels increased concomitantly as c-Src levels increased (Figure 15B). It is noteworthy 
that the observed increases in Mdm2 protein levels are independent of p53 as H1299 cells 
are devoid of p53. To verify that c-Src tyrosine phosphorylation of Mdm2 is required for 
the increase in Mdm2 protein levels, the Y281-302F Src-phosphorylation mutant of 
Mdm2 was used in transient transfection of H1299 cells. Overexpression of the Y281-
302F Mdm2 mutant, with or without CA-Src, in H1299 cells did not change Mdm2 
protein levels (Figure 16).  
To examine how c-Src regulates endogenous Mdm2 protein levels, we activated 
c-Src through epidermal growth factor (EGF) stimulation of MCF7 cells. MCF7 cells 
were serum-starved for 48 hr and then treated with 200 ng/mL of EGF for a time course 
of 2 hr. EGF stimulation resulted in an increase of Mdm2 protein levels with a peak 
achieved by 1 hr (Figure 17A). To ensure that this increase of Mdm2 by EGF  
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Figure 15: Overexpression of CA-Src increases Mdm2 protein levels 
(A) Western blot of Mdm2, Src, and GAPDH from extracts of H1299 cells ectopically 
expressing Mdm2, CA-Src, or KD-Src. (B) Western analysis of H1229 cells 
overexpressing Mdm2 and increasing concentrations (0.5, 1, 5, 10μg) of CA-Src. 
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Figure 16: Increases in Mdm2 protein levels by c-Src is dependent on c-Src 
phosphorylation sites Y281 and Y302 of Mdm2 
H1299 cells ectopically expressing Mdm2 Y281-302F and CA-Src. Western blot analysis 
was performed for Mdm2, c-Src, and GAPDH as indicated.  
48 
was due to c-Src activity, serum starved MCF7 cells were pre-treated with the c-Src 
inhibitor, PP1 or DMSO control for 1 hr before addition of EGF. While EGF alone 
resulted in an increase of Mdm2, exposure of cells to the c-Src inhibitor PP1 showed no 
apparent increase in Mdm2 (Figure 17B). Since Mdm2 levels are increased due to c-Src 
activation, then it would be anticipated that inhibition of c-Src should result in a decrease 
in Mdm2 levels. This observation was validated, as treatment of MCF7 cells with 
increasing PP1 concentrations resulted in a dose-dependent decrease in Mdm2 levels 
(Figure 17C). Thus, the increase in Mdm2 protein level is due to activated c-Src and the 
phosphorylation of Mdm2. 
While Mdm2 is a substrate for c-Src we could not exclude the possibility that the 
increased levels of Mdm2 was dependent on gene expression. To test if c-Src altered 
mdm2 gene expression, we conducted reporter assays using the mdm2 P2 promoter 
attached to luciferase. As anticipated, no difference was seen by overexpression of c-Src 
in H1299 cells or with inhibition of endogenous c-Src using PP1 treatment in MCF7 cells 
on the mdm2 promoter as determined by luciferase (Figure 18 A&B).  
Since we eliminated the contribution of gene expression to increasing Mdm2 
levels, we examined if c-Src would alter the half-life of Mdm2. To test the effect c-Src 
has on Mdm2 protein half-life, H1299 cells were transfected with Mdm2 plus Myc-LacZ 
for internal control and either CA-Src, KD-Src, or pUSE (Src vector control). After 
transfection (24 hr) the cells were treated with cyclohexamide to stop protein synthesis. 
The cells were then harvested at the indicated time points and subjected to 
immunoblotting to determine Mdm2 levels (Figure 19A). The protein levels were  
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Figure 17: Activation/inhibition of endogenous c-Src regulates endogenous Mdm2 
protein levels  
(A) MCF7 cells were serum-starved for 48 hr and then treated with 200 ng/mL of EGF 
for times indicated. Endogenous Mdm2 and GAPDH were analyzed by western blot. (B) 
MCF7 cells were serum starved for 48 hr and then pre-treated with either DMSO or PP1 
(10μM) for 1 hr prior to addition of EGF (200ng/mL). EGF treatment was for 1 hr 
followed by western analysis for Mdm2 and GAPDH. (C) MCF7 cells were treated with 
increasing concentrations (1, 5, 10, 15, and 20 μM) of PP1 for 16 hr and western blot was 
performed for Mdm2 and GAPDH.  
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Figure 18: c-Src does not induce Mdm2 transcription from the P2-promoter 
(A) Luciferase assay of the mdm2-P2-Luc with Myc-LacZ in H1299 cells alone or 
expressing CA-Src. (B) Luciferase activity was measured from of the mdm2-P2-Luc and 
Myc-LacZ in MCF7 cells after treatment with 10μM of PP1 or DMSO for 16 hr. Y-axis 
measurements are relative luciferase units (RLU), calculated from the ratio of 
luciferase/β-gal activity. Error bars represent standard deviation. 
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Figure 19: c-Src increases Mdm2 protein half-life 
(A) H1299 cells were transfected with Mdm2 and CA-Src, KD-Src or empty vector 
(pUSE) in the presence of Myc-LacZ vector. Twenty-four hr post-transfection the cells 
were treated with 50 μg/ml cyclohexamide (CHX) and harvested at different time points 
as indicated. The cell lysates were immunoblotted with anti-Mdm2 and anti-Myc 
antibodies as indicated. (B) The density of Mdm2 in each lane was quantified against the 
level of Myc-LacZ and plotted in a graph. 
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quantitated and graphed as a ratio of Mdm2/LacZ by measuring the intensity of each 
band. In the presence of KD-Src the half-life of Mdm2 was 25 min, which is consistent 
with published reports of Mdm2 half-life. Interestingly, in the presence of CA-Src the 
half-life of Mdm2 increased to 70 min (Figure 19B). However when the Mdm2 Y281-
302F mutant was co-expressed with CA-Src, the half-life remained at 25 min, the same as 
WT Mdm2 in the presence of KD-Src (Figure 20 A&B). Thus, c-Src phosphorylation of 
Mdm2 more than doubled the half-life of Mdm2.  
Since Mdm2 possesses the ability to function as an ubiquitin ligase, we wondered 
if c-Src phosphorylation might inhibit the ability of Mdm2 to be loaded with ubiquitin, 
which would contribute to the increase in protein stability. A transient assay was 
employed utilizing overexpressed and purified his-tagged ubiquitin protein conjugates. 
We found that in the presence of CA-Src that Mdm2 ubiquitination is greatly reduced 
(Figure 21). These experiments show that the increase in Mdm2 protein levels is due the 
lack of ubiquitin being loaded to Mdm2, subsequently resulting in stabilization of Mdm2.  
Since phosphorylation of Mdm2 by c-Src reduced loading of ubiquitin, we 
questioned whether it could still serve as an E3 ubiquitin ligase towards p53. To this end, 
an in vitro ubiquitination assay of p53 was performed using untreated or phosphorylated 
Mdm2. Phosphorylation was done with c-Src or c-Abl. c-Abl is known to inhibit Mdm2 
ubiquitination of p53, and thus served as a positive control. As shown in Figure 22, 
phosphorylation with c-Src inhibited the ubiquitination of p53 to the same extent as c-
Abl. Since Mdm2 was unable to ubiquitinate p53 in vitro, we tested for p53 protein levels 
in cells. H1299 cells were transfected with different combinations of p53, Mdm2, CA-
Src, and KD-Src. As expected, addition of Mdm2 resulted in a decrease of p53, but CA- 
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Figure 20: Y281 and Y302 of Mdm2 are required for c-Src mediated increase of 
Mdm2 half-life  
(A) H1299 cells were transfected with Y281-302F of Mdm2 and CA-Src, or KD-Src in 
the presence of Myc-LacZ vector. Twenty-four hr post-transfection the cells were treated 
with 50 μg/ml cyclohexamide (CHX) and harvested at different time points as indicated. 
The cell lysates were immunoblotted with anti-Mdm2 and anti-Myc antibodies as 
indicated. (B) The density of Mdm2 in each lane was quantified against the level of Myc-
LacZ and plotted in a graph. 
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Figure 21: Loss of Mdm2 ubiquitination by CA-Src 
(A) Western blot analysis of Mdm2 from a his-ubiquitin pull-down assay. His-ubiquitin 
conjugates were purified from H1299 cells transfected with Mdm2, CA-Src and His-
ubiquitin (left). Western blotting from lysates shows expression of Mdm2, Src and 
GAPDH. 
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Figure 22: c-Src inhibits Mdm2 mediated ubiquitination of p53  
In vitro ubiquitination assay of recombinant p53 using Mdm2 or Mdm2 phosphorylated 
by c-Src or c-Abl. Western blot was probed for p53. E1, E2, and ubiquitin were added as 
indicated.  
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 Src prevented Mdm2-mediated degradation of p53, while KD-Src had no such effect 
(Figure 23A). To examine endogenous p53 levels, MCF 7 cells were transfected with 
increasing amounts of CA-Src. As seen with the overexpression, endogenous levels of 
p53 increased with c-Src expression and this increase of p53 correlated directly with the 
increase of Mdm2 (Figure 23B). Furthermore, activation of endogenous c-Src by EGF 
over a 1 hr time course resulted in a similar increase in p53 that mimics the increases of 
c-Src and Mdm2 protein levels (Figure 24A). Additionally, inhibition of endogenous c-
Src with PP1 resulted in a dose dependent decrease in p53 levels (Figure 24B). These 
results support the observation that c-Src phosphorylation of Mdm2 results in 
stabilization of p53 levels due to Mdm2 inability to function as an ubiquitin ligase. Since 
Mdm2 could not ubiquitinate p53, we needed to determine if this stability would coincide 
with an increase in p53 activity. Using the PG13-Luc, which is an artificial p53 promoter 
attached to luciferase, along with combinations of p53, Mdm2, CA-Src and KD-Src we 
observed that p53 activity was decreased in the presence of Mdm2 as expected. However, 
p53 activity was further decreased by an additional 60% in the presence of CA-Src and 
reverted to the same level of Mdm2 alone in the presence of KD-Src. These data show 
that Mdm2 inhibition of p53 is further enhanced in the presence of CA-Src (Figure 25A), 
even though p53 protein levels are stabilized.  
Mdm2 can inhibit p53 just though binding, yet the c-Src-phosphorylation sites 
suggest that this inhibition is not dependent on increasing the p53-Mdm2 complex. To 
test if this was evident, we conducted a luciferase assay using the ligase dead mutant 
C464S of Mdm2. H1299 cells were again transfected with the PG-13-Luc along with 
p53, C464S, and CA-Src. The luciferase assay showed that p53 activity was decreased in  
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Figure 23: Exogenous CA-Src elevates p53 protein levels 
(A) Western blot analysis of lysates from H1299 cells overexpressing p53, Mdm2, CA-
Src, and KD-Src. (B) Western blot was performed to examine endogenous levels of 
Mdm2, p53, GAPDH, and expression of Src from lysates of MCF7 cells ectopically 
expressing CA-Src. 
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Figure 24: Activation/Inhibition of endogenous c-Src regulates endogenous p53 
protein levels 
(A) Western blot analysis was performed for Mdm2, p53, activated Src (p-Src Y419) and 
GAPDH from MCF7 cells serum starved for 48 hr and incubated with EGF over a time 
course of 1hr. (B) Western blot of p53 from MCF7 cell extracts treated for 16 hr with 
increasing concentrations of PP1 (1, 5, 10, 15, 20 μM). 
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Figure 25: c-Src inhibits p53 transcriptional activity dependent on Mdm2 ligase 
activity  
(A) Luciferase assay of the PG13-sythetic promoter and Myc-LacZ in H1299 cells 
transfected with p53, Mdm2, CA-Src, and KD-Src. (B) Luciferase assay using PG-13-
Luc and Myc-LacZ in H1299 cells transfected with p53, Mdm2 C464S, and CA-Src. *,# 
represents statistical significance of p<0.05. Y-axis measurements are relative luciferase 
units (RLU). The RLU was calculated from the ratio of luciferase/β-gal activity. Error 
bars represent standard deviation of at least three experiments.  
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the presence of C464S Mdm2 but was not dramatically increased with CA-Src (Figure 
25B). This experiment provides direct evidence that there is a dependence on the RING 
domain of Mdm2 for c-Src to fully inactivate p53.  
We have shown that p53 protein levels are stabilized but transcriptionally inactive 
and that this inhibition is dependent on an intact Mdm2 RING finger and c-Src 
phosphorylation. Because of these observations, we examined if c-Src phosphorylated 
Mdm2 could still function as a neddylating enzyme. To test this, H1299 cells were 
transfected with a His-nedd8 construct along with p53, Mdm2, and CA-Src or KD-Src. A 
nickel pulldown assay was used to isolate neddylated proteins. Figure 25A illustrates that 
in the presence of CA-Src, neddylated p53 dramatically increases. When the immunoblot 
was stripped and re-probed with anti-Mdm2 antibodies, we were able to detect an 
increase in Mdm2-nedd8 conjugates in the presence of CA-Src. Interestingly, nedd8 
conjugated to p53 or Mdm2 was absent when KD-Src was present (Figure 26A). This 
indicates that c-Src phosphorylation of Mdm2 is activating the neddylating activity of 
Mdm2.  
To provide further evidence that this switch of Mdm2 activity was dependent on 
Src-phosphorylation Mdm2, a His-nedd8 pulldown assay using the phosphorylation 
deficient mutant Y281-302F was performed. This result shows that p53 neddylation 
increases dramatically in the presence of WT Mdm2 and CA-Src, but there was no 
change in p53 neddylation in the presence of Y281-302F and CA-Src (Figure 26B).  
61 
 
 
 
Figure 26: c-Src activates Mdm2 neddylation activity, dependent on Y281 and Y302 
(A) Western blot of p53 and Mdm2 from His-nedd8 pull-down assay of H1299 cells 
expressing His-nedd8, p53, WT-Mdm2, CA-Src, and KD-Src. To verify expression, 
lysates were subjected to western analysis as indicated. (B) His-nedd8 pulldown was 
performed as in (A), but with the use of Mdm2 Y281-302F as indicated. 
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Since our transient transfection data indicated that Mdm2 can function as a 
neddylating enzyme, we examined the effect of inhibiting neddylation by 
pharmacological agents. H1299 cells transfected with p53, Mdm2, and CA-Src and 
treated with the neddylation inhibitor, MLN4924, showed a loss of neddylated p53 
(Figure 27). This result would be anticipated as c-Src directs Mdm2 to switch and 
become a neddylating enzyme, and nedd8 would not be loaded to Mdm2. To integrate the 
role of c-Src on endogenous neddylation of p53, the c-Src inhibitor PP1 was used. MCF7 
cells were treated with PP1, and p53 was immunoprecipitated from cell extracts. 
Immunoblot analysis was done using anti-nedd8. Figure 28 shows that inhibition of c-Src 
using PP1 results in a decrease in endogenous neddylated p53. Since Mdm2 ligase 
activity is specified by which E2 (ubiquitin or neddylation) it binds, we hypothesized that 
c-Src phosphorylation of Mdm2 might inhibit or enhance interactions with a specific E2. 
Recombinant GST-Ubc5 (ubiquitin E2) and GST-Ubc12 (neddylation E2) were 
incubated with Mdm2 or phosphorylated Mdm2 and a GST pulldown assay performed. 
As shown in Figure 29, c-Src phosphorylation of Mdm2 resulted in a substantial decrease 
in the Ubc5/Mdm2 interaction compared to unphosphorylated Mdm2. Meanwhile the 
Ubc12/Mdm2 interaction showed a slight increase after Mdm2 phosphorylation. This 
experiment provides evidence that the mechanism of c-Src activation of Mdm2 
neddylation activity may involve changes in specific E2 recruitment. Taken together, 
these results show that c-Src phosphorylation of Mdm2 activates the neddylation activity 
of Mdm2. 
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Figure 27: MLN4924 decreases c-Src dependent modifications of p53  
(A) Western blot of p53 and GAPDH from H1299 extracts overexpressing p53, Mdm2, 
and CA-Src. 24 hr post-transfection, cells were treated with either DMSO or 0.3 μM of 
MLN4924 for 16 hr. 
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Figure 28: Inhibition of c-Src results in loss of endogenous neddylated p53  
Western blot of p53 immunoprecipitated from MCF7 cells after treatment with PP1 or 
DMSO for 16 hr. Western blot analysis for nedd8 was done to determine amount of 
nedd8-conjugated p53.  
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Figure 29: Specific in vitro E2 requirement to Mdm2 by c-Src phosphorylation 
Western blot of GST-pulldown of GST-Ubc5 and GST-Ubc12 with Mdm2 or c-Src 
phosphorylated Mdm2. GST alone was used as negative control. 
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Figure 30: Inhibition of neddylation reverses c-Src downregulation of p53 
transcriptional activity 
PG13-Luc activity was assayed using H1299 cells transfected with Myc-LacZ, p53, 
Mdm2, and CA-Src. 24 hr post-transfection cells were treated with DMSO or 0.3 μM of 
the NAE inhibitor MLN4924 for 16 hr. *, # represent statistical significance of p<0.05. 
Y-axis measurements are relative luciferase units (RLU). The RLU was calculated from 
the ratio of luciferase/β-gal activity. Error bars represent standard deviation. 
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Since c-Src phosphorylation of Mdm2 directs ligase activity towards neddylation, we 
tested what effect inhibition of neddylation would have on p53 activity. H1299 cells were 
transfected with the PG-13-Luc, p53, Mdm2 and CA-Src. Reduction in p53 activity by 
Mdm2 was further increased in the presence of c-Src as expected. Treatment of H1299 
cells with MLN4924 restores p53 activity to levels observed with Mdm2 alone, thereby 
supporting an Src-Mdm2-nedd8 pathway that inactivates p53 (Figure 30). Since the 
PG13-Luc is a synthetic construct we wanted to find a more relevant physiological 
promoter. Since both c-Src and Mdm2 are intimately linked to regulation of angiogenic 
processes, such as the positive regulation of VEGF (64, 106), we next determined what 
effect c-Src phosphorylation of Mdm2 would have on an anti-angiogenic target. The 
tumor suppressor maspin is a p53 target that plays an important role in regulating tumor 
cell invasion and metastasis (107). We have previously shown that p53 is required for the 
upregulation of Maspin protein levels under hypoxic conditions in glioblastoma cell lines 
(108). To assess Src-phosphorylated Mdm2 effect on p53-induced maspin, a luciferase 
assay utilizing the maspin promoter was performed. As shown in Figure 31A, H1299 
cells transfected with the maspin promoter attached to the luciferase gene (maspin-Luc) 
shows that p53 drives the expression of luciferase from the maspin promoter and that a 
decrease is seen with Mdm2 overexpression. Just like with the PG13-Luc, expression of 
CA-Src further inhibits p53 activity on the maspin promoter and the inhibition is 
dependent on neddylation. To ensure that the decrease seen on the maspin promoter was 
due to c-Src phosphorylation of Mdm2, another luciferase assay was done using the 
Y281-302F Mdm2 and CA-Src. Here the maspin promoter luciferase decreased with the 
addition of Mdm2 Y281-Y302F, but the addition of CA-Src did not result in an increase  
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Figure 31: Inhibition of maspin promoter by c-Src is dependent on neddylation and 
Mdm2 Y281/Y302 
(A) Maspin-Luc activity was assayed using H1299 cells transfected with Myc-LacZ, p53, 
Mdm2, and CA-Src. Post-transfection (24 hr) cells were treated with DMSO or 0.3 μM of 
the NAE inhibitor MLN4924 for 16 hr. (B) Luciferase assay of maspin-Luc in H1299 
cells using p53, Mdm2 Y281-302F, and CA-Src.*, # represents statistical significance of 
p<0.05. Y-axis measurements are relative luciferase units (RLU). The RLU was 
calculated from the ratio of luciferase/β-gal activity. Error bars represent standard 
deviation. 
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of inhibition as seen with WT Mdm2 (Figure 31B). This shows that the enhancement of 
inhibition seen on the maspin promoter by c-Src is dependent on Mdm2 Y281 and Y302. 
For further insight on how endogenous neddylation of p53 would affect maspin levels, 
MCF7 cells were transfected with the maspin-Luc construct or a mutant maspin-Luc 
(MT1) that is unresponsive to p53, to insure luciferase activity was dependent on p53. c-
Src was then inhibited for 16 hr using PP1 and a luciferase assay performed. Inactivation 
of c-Src allowed for an increase of p53 activity on the maspin-Luc construct (Figure 
32A). This increase of p53 activity was also seen at the protein level, as Maspin protein 
was increased following inhibition of c-Src (Figure 32B). These findings provide insight 
into the regulation of c-Src-induced neddylation of p53. This neddylation event is 
responsible for the further reduction in p53 activity on both the PG-13-Luc and on its 
ability to activate the tumor suppressor Maspin.  
 
3.3 Discussion 
Understanding how Mdm2 functions in tumor progression is of critical 
importance since Mdm2 protein levels are detectable in 40-80% of high-grade human 
malignances and 10% show mdm2 gene amplification (4). The current paradigm is that 
Mdm2 upregulation would inhibit the p53 tumor suppressor, through destabilization, 
resulting in tumor progression. However there are many human cancers, including breast, 
gliomas, oral, renal, and cervical, that have elevated levels of Mdm2 and wild-type p53 
(109-113). This correlation of high Mdm2 and p53 levels indicate that Mdm2 may have 
other possible mechanisms for the inactivation of p53, besides destabilization. The Mdm2 
protein has been shown to conjugate a nedd8 molecule to p53 that inactivates its  
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Figure 32: Inhibition of c-Src upregulates maspin transcription and protein levels  
(A) Luciferase assay of MCF7 transfected with either maspin-Luc or mutant maspin-Luc 
(MT1) and Myc-LacZ. After transfection (24 hr) cells were treated with DMSO or 10 μM 
PP1 for 16 hr. (B) Western blot analysis of MCF7 cells treated with DMSO or 10μM 
PP1for 16 hr. 
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transcriptional activity without affecting its protein stability, but the mechanism has 
remained elusive (22). 
 The non-receptor tyrosine kinase c-Src regulates a number of normal and 
pathological processes including proliferation, survival, motility, and angiogenesis (71). 
c-Src functions poorly as an oncogenic factor on its own and activating mutations of c-
Src in human cancer are rare. This has led to the view that c-Src may facilitate and  
promote the activity of other proteins, as opposed to being an autonomous dominant 
transforming agent on its own. One c-Src interacting protein that has been extensively 
studied is EGFR. This interaction results in phosphorylation of EGFR at Y845, and is c-
Src dependent (114). This pathway activates STAT5b (115) and mediates proliferation 
and promotes cell survival through cyclooxygenase 2 (COXII) (116). FAK also interacts 
with c-Src. FAK mediates cancer metastasis by regulating focal adhesion formation and 
turnover. c-Src phosphorylation activates FAK kinase activity and generates docking 
sites for Grb2 and other signaling molecules that regulate signaling pathways (117). In 
this study we provide evidence that c-Src cooperates with Mdm2 to enhance oncogenic 
activities.  
Our data shows that Mdm2 interacts with and is phosphorylated by c-Src (Figures 
9A, 10, 12, 14A&B). We demonstrate through in vitro GST pull-down assays and an 
immunoprecipitation from MCF7 cells that the Mdm2/Src interaction takes place both in 
vitro and in vivo. c-Src uses its SH3 protein domain for many of its protein-protein 
interactions including those with paxillin and p85. Here the c-Src SH3 domain is 
sufficient for binding to Mdm2. Also, through the use of truncation mutants of Mdm2 we 
narrowed down the c-Src binding to amino acids 90-268 of Mdm2 (Figure 9B). 
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Interestingly, this truncation of Mdm2 encompasses the acidic domain, which is known to 
contain many serine residues that are normally phosphorylated under non-stress 
conditions (118). One hypothesis is that these modifications could enhance c-Src binding 
of Mdm2. Hence any alteration to these modifications, such as dephosphorylation of by 
PP2A (119), or any other protein interactions driven by cellular stresses could represent a 
mechanism to regulate the c-Src-Mdm2 interaction. The phosphorylation of Mdm2 by c-
Src occurs on tyrosine 281 and 302. In vitro kinase reactions revealed that both Y281 and 
Y302 have to be mutated to phenylalanine to inhibit c-Src mediated phosphorylation of 
Mdm2 (Figure 13). Through the use of ectopically expressed c-Src or activation by EGF, 
we show that c-Src phosphorylation of Mdm2 results in an increase in Mdm2 protein 
levels (Figure 15 A&B, 17 A-C). These c-Src phosphorylation sites are within or near the 
zinc finger domain of Mdm2. Recent work has shown that a mutation in the zinc finger 
domain (C305F) has an enhanced half-life compared to wild-type (120). Interestingly, c-
Src phosphorylation of Mdm2 showed similar results (Figure 19 A&B) and mutation of 
the two c-Src sites resulted in no change in half-life (Figure 20 A&B). Taken together 
these results could hint that alteration of the Mdm2 zinc finger domain could have great 
implication for protein stability.  
 The E3 ubiquitin ligase activity of Mdm2 has been extensively studied, especially 
in regard to p53 degradation. We have previously shown that after DNA damage c-Abl 
phosphorylation of Mdm2 at Y276 and Y394 enhances complex formation with Mdmx. 
This complex leads to degradation of both Mdm2 and Mdmx and results in the 
stabilization of p53 (48). Yet how growth factor activated tyrosine kinases affects Mdm2 
ubiquitin ligase activity has not been determined. Utilizing an in vitro ubiquitin ligase 
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assay, c-Src inhibited Mdm2 mediated ubiquitination of p53 to the same extent as c-Abl 
(Figure 22). This decrease in ubiquitination translated into p53 protein stability in H1299 
cells ectopically expressing p53 (Figure 23 A). Treatment with EGF also revealed a 
stabilization of p53 that correlated directly with increases in Mdm2 and activated c-Src 
protein (Figure 24A). To compensate for this increase in p53 protein levels, c-Src 
phosphorylation of Mdm2 further reduced p53 transcriptional activity in an Mdm2 RING 
finger dependent manner (Figure 25 A&B). These results are in direct opposition of the 
effect c-Abl phosphorylation signaling to Mdm2 has on p53 transcriptional activity. This 
provides evidence that tyrosine phosphorylation of Mdm2 under different conditions, 
may have different effects on p53 transcriptional activity, while maintaining protein 
levels. Interestingly, this induction of protein levels coupled with concurrent inhibition of 
transcriptional activity is not unheard of in the p53 family. It has been reported that p73 
when bound to Mdm2 results in p73 stabilization, but leads to inhibition of its 
transcriptional activity (51). Similarly, the c-Src family member Hck, has been shown to 
phosphorylate p73 resulting in protein stability but decreases in its activity (121). These 
findings support the notion that increases in p53 protein levels do not guarantee 
transcriptional activation.  
 The decrease in p53 transcriptional activity by c-Src could be explained by the 
increase of Mdm2 protein and half-life. Even without the ability to degrade p53 by 
ubiquitin ligase activity, Mdm2 is still capable of inhibition by masking p53's N-terminal 
transactivation domain (122). This is evident as the RING finger dead mutant of Mdm2, 
C464S, is still efficient at inhibiting p53 transcriptional activity. Our data illustrate that 
the RING domain of Mdm2 is required for a more dramatic reduction in p53 activity in 
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the presence of CA-Src (Figure 25B). The Mdm2 protein has dual ligase activity capable 
of conjugating ubiquitin and nedd8. A previous report has shown that the histone acetyl 
transferase Tip60 can inhibit Mdm2 mediated neddylation of p53, but not ubiquitination 
(123). Also the original study showing p53 neddylation showed that CHO-TS-41 cells, 
which have a temperature sensitive mutation in the APP-BP1 gene inhibiting neddylation, 
still have ubiquitinated p53 even in the absence of neddylation (22). These studies taken 
together reveal that Mdm2 ligase activities can be both separately and individually 
regulated. However, signaling events regulating the activation of Mdm2 neddylation 
activity have yet to be identified. Our data reveal that c-Src phosphorylation of Mdm2 
results in increased neddylated p53 and Mdm2. This increase in neddylation of p53 is 
dependent on the c-Src phosphorylation, as the Y281-302F Mdm2 mutant did not 
increase neddylated p53 and inhibition of c-Src by PP1 resulted in less nedd8 bound to 
p53 endogenously (Figure 26 A&B, 28). It appears that c-Src may regulate this switch by 
determining which E2 is able to bind to Mdm2 (Figure 29). Furthermore, using the 
inhibitor of neddylation, MLN4924, the inhibition on both the PG13-Luc promoter and 
the maspin-Luc promoter by Mdm2 in the presence of Src was reversed (Figure 30, 31). 
The effect on the maspin promoter is especially interesting due to the role of Maspin as a 
tumor suppressor in breast cancer. Maspin is normally highly expressed in normal breast 
epithelial cells, but is down regulated in invasive and metastatic breast carcinoma cells 
(83). Maspin tumor suppressor activity was validated as stable transfection of maspin in 
breast cancer cell lines led to an inhibition of tumor cell invasion in vitro and a decrease 
in tumor metastasis in mice (124, 125). The ability of Maspin to inhibit tumor growth 
was linked to its inhibition of tumor-induced angiogenesis. Maspin protein blocked 
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endothelial cell migration in response to growth signals and inhibited endothelial tube 
formation in vitro (91). Also, Maspin expression correlated with decreased micro-vessel 
staining in human breast cancer samples (126). This is important as both Mdm2 and c-Src 
have been linked to angiogenesis and metastasis in breast cancer, and here we show that 
inhibition of c-Src using PP1 results in greater activity of the maspin-Luc and greater 
Maspin protein levels in the breast cancer cell line, MCF7 (Figure 32 A&B). Taken 
together, these experiments prove that neddylation is a key component in c-Src ability to 
inhibit the p53/maspin tumor suppressor network though Mdm2 (Figure 33). 
 The data presented here reveal a novel c-Src /Mdm2/p53/Maspin pathway. This 
signaling cascade could be responsible for the high levels of Mdm2 seen in numerous 
cancers that still maintain wild-type p53. We also show that this pathway has a direct 
influence on the levels of the tumor suppressor maspin and might have implications in 
tumor angiogenesis. Thus, future treatment options might benefit from inhibition of c-Src 
and/or neddylation to engage the p53/Maspin anti-angiogenic pathway.  
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Figure 33: Model of c-Src phosphorylation of Mdm2 and its downstream effects 
Phosphorylation of Mdm2 by c-Src at Y281 and Y302 switches Mdm2 ligase activity to a 
neddylating enzyme, reducing p53 transcriptional activity on target genes, including 
Maspin. Inhibitors of both c-Src and neddylation can be used to inhibit this pathway.  
77 
4. Mdm2 enhances breast cancer metastasis  
4.1 Introduction 
In the United States, women will have a 1 in 8 chance of developing breast cancer 
in their lifetime (127). There are two main types of breast cancer. The first is ductal 
carcinoma, which starts in the ducts that move milk from the breast to the nipple. The 
other is lobular carcinoma and it starts in the lobules, which produce the milk. Breast 
cancer is a heterogeneous disease but has clinically distinct subtypes based on the 
expression of molecular markers. These markers include hormone receptor (HR), 
progesterone receptor (PR), and Her2. Another subtype of breast cancer termed, triple 
negative breast cancer, is diagnosed on the absence of all 3 of these markers, and carries 
the basal like molecular profile (128). Metastasis, the process by which tumor cells 
invade and colonize distal sites, is the leading cause of death, due to organ failure, for 
breast cancer patients. Breast cancer has five primary sites of metastasis including lung, 
bone, lymph nodes, liver and pleura. Metastatic tumors at these sites can be seen in over 
 50% of patients at autopsy, providing evidence of how frequently breast cancer is able to 
undergo metastasis (129).  
While there are many factors that regulate tumor metastasis, recent work has 
implicated the Mdm2 network in this process. One study by Wang et al., illustrated how 
Mdm2, through wild-type 53, is responsible for the ubiquitination and degradation of 
Slug in lung cancer (130). Slug is a major transcriptional repressor of E-Cadherin, and 
can trigger EMT. Interestingly, it was also shown that E-Cadherin itself can interact with 
and undergo ubiquitination by Mdm2. Primary tumors from breast cancer patients had an 
inverse correlation between Mdm2 and E-cadherin protein levels as seen by 
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immunohistochemistry. These high Mdm2/low E-cadherin levels were associated with 
lymph node metastasis (63). We have reported that Mdm2 is upregulated in many late 
stage breast cancers, due to a tumor growth factor (TGF)-β/Smad3 signaling event that 
drives transcription of Mdm2. We demonstrated that approximately 65% of late-stage 
carcinomas were positive for activated Smad3 and Mdm2, indicating a strong correlation 
between TGF-β1-mediated induction of Mdm2 and late-stage tumor progression. 
Furthermore 73% of the carcinomas that had known metastases stained for Mdm2 and 
activated Smad3, possibly linking Mdm2 to a role in breast cancer metastasis (11). 
 Two in vivo studies have also tried to elucidate the role of Mdm2 in metastasis. 
First, Zhang and Hill, showed that overexpression of Mdm2 in KHT cells resulted in 
more lung metastasis after tail vein injection (131). Meanwhile, an orthotopic pancreatic 
model using lentiviral knockdown of Mdm2, showed that tumor growth and metastasis 
was decreased in tumors with lower levels of Mdm2 (132). However, both studies 
concluded that the metastatic potential provided by Mdm2 was due to its regulation of 
wild-type p53. While Mdm2 main function is attributed to the regulation of p53, it has 
also been shown to promote tumorigenesis independent of p53. For example Mdm2 
splice variants unable to bind p53 can still promote transformation and p53-null 
transgenic mice overexpressing Mdm2 have a higher incidence of tumors compared to 
littermate controls (133, 134). These experiments provide evidence that Mdm2 can 
promote tumor growth in the absence of p53. But the question remains if Mdm2 can 
facilitate metastasis in a p53-independent manner?  
To answer this question we employed a known orthotopic mouse model of breast 
cancer metastasis. We used the TMD-231 cell line, which are derived from MDA-MB-
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231 cells that had been grown in the mammary fat pad of mice. The MDA-MB-231 is the 
most widely used and characterized cell line for tissue specific metastasis of human 
breast cancer. The MDA-MB-231 cell is derived from the pleural effusion of a late stage 
breast cancer patient who died with multiple metastases (135). We chose these cells, as 
they are known to metastasize to the lung and also contain mutant p53. The mutation is 
R280K and is located in the DNA binding domain and inactivates p53 DNA binding 
activity. Thus, this allows us to study Mdm2’s role in metastasis independent of p53 
activity. To this end, we used a lentiviral construct harboring shRNA to knockdown 
Mdm2 in the TMD-231 cell line. We show that knockdown of Mdm2 has no effect on 
TMD-231 cellular growth in vitro or cell cycle progression, but knockdown of Mdm2 did 
result in decreased invasive potential. Interestingly, knockdown of Mdm2 did slow tumor 
growth in vivo, possible due to a decreased affinity for binding to fibronectin. Most 
importantly, we found that knockdown of Mdm2 showed a dramatic loss in breast to lung 
metastasis. This loss of metastatic potential was due to a reduction in HIF-1α and VEGF 
protein levels leading to a loss of primary tumor vascularization. Here we provide 
definitive evidence Mdm2 can enhance tumor metastasis, independent of p53.  
  
4.2 Results 
Mdm2 expression correlates with metastasis in both pancreatic and breast cancer 
models (131, 132). However all studies to date have determined that the role of Mdm2 in 
metastasis is due to the regulation of wild-type p53. No studies however, have 
determined if Mdm2 plays a role in metastasis independent of p53. To determine if 
Mdm2 has a p53-independent role in this process, we used the TMD-231 cell line, which 
harbors mutant p53 (R280K), and generated a knockdown of Mdm2 using a lentiviral 
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vector harboring shRNA. Western blot analysis in Figure 34A shows that Mdm2 was 
knockdowned in the shMdm2 compared to shGFP control cells. While Mdm2 is the main 
E3 ubiquitin ligase for the wild-type p53, it has also been shown to ubiquitinate mutant 
p53 (136). It has been established that mutant p53 can promote metastasis through its 
gain of function properties, including interacting with p63 and p73, and inhibiting their 
tumor suppressor functions (137). To ensure that any changes in metastatic potential in 
cells with shMdm2 was not due to mutant p53 levels, western analysis for mutant p53 
was performed. ShMdm2 had no detectable increases in mutant p53 levels compared to 
shGFP cells ensuring that any changes in metastasis would not be due to levels of mutant 
p53 (Figure 34B).  
Mdm2 has been shown to promote positive effects on cell proliferation, through 
its binding to Rb, and Cyclin A (54, 138). Thus, it was necessary to determine if 
knockdown of Mdm2 would inhibit TMD-231 cell proliferation and cell cycle 
progression. First, shGFP and shMdm2 TMD-231 cells were plated and grown for 96 hr.  
Knockdown of Mdm2 did not show any inhibition of proliferation of TMD-231 cells up 
to 96 hr, when normalized to the 24 hr time point (Figure 35A). For cell cycle analysis, 
shGFP and shMdm2 TMD-231 cells were serum starved for 24 hr. After the addition of 
serum no changes in cell cycle was seen at any time point (Figure 35B). Since no 
differences in proliferation were observed, we hypothesized that knockdown of Mdm2 in 
TMD-231 cells would lead to inhibition of their ability to migrate and invade, as has been 
reported in other cell lines (63, 139). A Matrigel Invasion Assay was employed, using 
serum as a chemoattractant, and showed that 70% of shGFP cells were able to migrate 
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Figure 34: Analysis of Mdm2 and p53 protein levels in shGFP and shMdm2 TMD-
231 cells 
(A) Western blot analysis of Mdm2 and GAPDH in shGFP and shMdm2 TMD-231 cells. 
(B) Western blot analysis of p53 and GAPDH in shGFP and shMdm2 TMD-231 cells.  
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Figure 35: Growth and cell cycle analysis of TMD-231 shGFP and shMdm2 cells 
(A) TMD-231 cells were grown for 96 hr with cell counts taken at 24 hr intervals. Cell 
counts are normalized to 24 hr time point, to account for differences in plating 
efficiencies. (B) Cell cycle analysis of TMD-231 cells that were serum starved for 24 hr 
followed by addition of 1% serum for times indicated.  
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Figure 36: In vitro invasion potential of shGFP and shMdm2 TMD-231 cells  
shGFP and shMdm2 cells were plated in 8 m Matrigel chambers and allowed to invade 
for 22 hr using serum as a chemoattractant. Cells were counted in three random 25X 
fields and experiments were done in triplicate. Percent invasion was determined as 
defined in Materials and Methods. Error bars represent standard deviation. 
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Figure 37: In vivo tumor growth and final tumor weights  
(A) Graph of tumor volumes over time of shGFP and shMdm2 TMD-231 cells implanted 
into the mammary fat pad of mice. Tumors were harvested when average volume of 
group was 600 mm. (B) Final tumor weights after harvest from both TMD-231 tumor 
groups. Error bars represent standard deviation.  
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through the chamber compared to only 42% of the shMdm2 cells (Figure 36). These 
experiments indicate that knockdown of Mdm2 in TMD-231 cells does not affect their 
proliferation or cell cycle progression, but does hinder the ability of the cells to migrate 
and invade through Matrigel.  
Since knockdown of Mdm2 reduced the ability of TMD-231 cells to migrate 
though the Matrigel, we were interested to determine if Mdm2 would affect invasion and 
metastasis in vivo. To this end, we implanted shGFP and shMdm2 TMD-231 cells into 
the mammary fat pad of 6 week old γ-null NOD-SCID mice. To ensure that any 
differences seen in metastasis were due to Mdm2 loss and not tumor size or weight, each 
group was harvested when they reached an average final volume of 600mm. At the time 
of harvest the average tumor weight from each group was identical (1.1g) (Figure 37B). 
Interestingly the shMdm2 tumors grew at a slower rate, requiring an extra 2 weeks to 
reach the final volume (Figure 37A). However we noted that the delayed in growth 
appeared to occur in the initial time after implantation, thus we wondered if the shMdm2 
cells may have a problem seeding in an in vivo environment. It has been shown that 
Mdm2 can have effects on extracellular proteins involved with cell attachment (140, 
141). Interestingly, shMdm2 cells ability to bind to plates coated with fibronectin was 
decreased by 40% (Figure 38). This provides evidence that the shMdm2 cells may take 
longer to adhere in the mammary fat pad and could explain the delayed growth in vivo.  
The TMD-2331 cell line is a model of breast cancer metastasis to the lung (142). 
To determine if Mdm2 had any role in this metastatic process we harvested the lungs 
from both shGFP (n=10) and shMdm2 (N=10) and H&E was performed. All metastases 
were counted in both the right and left lobe of the lung. The shGFP lungs had an average 
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Figure 38: shMdm2 cells have diminished ability to bind fibronectin 
shGFP and shMdm2 cells were plated on cell culture dishes that were coated with 5μg/ml 
fibronectin. Cells were incubated for 30 min and then removed and counted. Error bars 
represent standard deviation.  
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Figure 39: Lung metastatic potential of shGFP and shMdm2 tumors 
Lung metastatic legions from both tumor groups were counted as described in Materials 
& Methods.  
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Figure 40: Loss of CD-31 staining in shMdm2 tumors 
(A) Tumors from shGFP and shMdm2 were stained for CD-31 using 
immunohistochemistry. (B) Bar graph representing quantification of CD-31 stating in 
shGFP and shMdm2 tumors. Three separate 25x fields from 4 different tumors were 
counted. Error bars represent standard deviation. * represents statistical significance of 
p<0.05. 
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of 315 metastases per lung, with each lobe accounting for about half the total number. 
However the shMdm2 had only an average of 130 metastases per lung, a statistically 
significant decrease of 60% compared to the shGFP (Figure 39). While the Mdm2 
knockdown affected the total number of metastatic foci, it did not affect the size of the 
lesions, as both small and large metastases were noted in both the shGFP and shMdm2 
groups. These results definitively show that Mdm2 is involved in breast cancer 
metastases to the lung.  
Angiogenesis, the formation of new blood vessels from pre-existing ones, is 
essential in helping tumor cells metastasize. Interestingly Mdm2 has been shown to have 
numerous angiogenic functions. We have previously shown that Mdm2 can bind to HIF-
1α resulting in the up regulation of the pro-angiogenic factor VEGF (64). Mdm2 can also 
stabilize VEGF mRNA levels promoting angiogenesis (143). In light of this evidence, we 
wondered if the tumors harboring knockdown of Mdm2 would be less vascularized. The 
vessels of the primary tumors were stained with CD-31 and the numbers of blood vessels 
were counted in multiple fields (Figure 40A). The shGFP showed an average  
of 38 vessels per field while the shMdm2 tumors only had an average of 28, a significant 
reduction in the amount of blood vessels by 25% (Figure 40B) from four tumors. To 
verify that the decrease seen in vascularization was due to changes in HIF-1α and VEGF 
protein levels, western blot analysis of both cell lines and tumors were performed. Figure 
41A shows that HIF-1α protein levels are higher in shGFP cells compared to shMdm2 
cells under both normoxic and hypoxic conditions. The same results were seen with 
VEGF protein levels (Figure 41B). As expected, HIF-1α protein levels in the tumors 
correlated exactly with the results from tissue culture. Four primary tumors from both  
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Figure 41: Mdm2 increases HIF-1 and VEGF protein levels in vitro 
(A) TMD-231 cells were placed under normoxic or hypoxic conditions and western blot 
analysis was performed for HIF-1 and GAPDH. (B) Western analysis of Mdm2 and 
VEGF from shGFP and shMdm2 TMD-231 cells, under normoxic or hypoxic conditions.  
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Figure 42: Mdm2 increases HIF-1α protein levels in tumors  
Tumors excised from the mammary fat pad of mice were lysed and western blotting 
performed for HIF-1, Mdm2, and Tubulin.  
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Figure 43: Mdm2 augments protein levels of lung metastasis genes  
Western blot analyses of MMP-2, SPARC, and GAPDH from shGFP and shMdm2 
TMD-231 cells.  
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shGFP and shMdm2 showed that Mdm2 and HIF-1α are all lower in the shMdm2 tumors 
(Figure 42). These results show that knockdown of Mdm2 results in lower levels of HIF-
1α and VEGF. This loss of pro-angiogenic factors lowers tumor vascularization, thus 
leading to a decrease in lung metastasis. 
Since Mdm2 facilitates many functions in the cell, we hypothesized that Mdm2 
could be regulating other pro-metastatic proteins or pathways. Minn et al. recently 
performed gene-array analysis and generated a list of gene candidates that could mediate  
breast cancer to lung metastasis (144). From this list we found that both MMP-2 and 
SPARC protein levels were down regulated in shMdm2 cells compared with shGFP, 
hinting that Mdm2 could be promoting or regulating a pro-metastatic gene profile for 
lung metastases (Figure 43). Further work is needed to determine the mechanism by 
which Mdm2 is regulating these genes. 
 
4.3 Discussion 
The Mdm2 onco-protein is implicated in a variety of p53-independent cellular 
processes including transcription regulation, translation control, DNA repair, and cell 
cycle regulation, all in addition to its role as the primary regulator of p53. Understanding 
how Mdm2 is regulating different tumorigenic properties is important treatment of 
malignancies in the clinic. Mdm2 overexpression correlates with poor patient prognosis 
and is seen in a variety of human cancers including 1/3 of sarcomas and cancers of the 
brain, breast, ovary cervix, lung, colon, and prostate (4, 5). The role for Mdm2 in 
promoting tumorigenesis is well established in both p53 dependent and independent 
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manner. Recent studies have also implicated Mdm2 in the process of tumor metastasis, 
but it has not been determined if this role is dependent on p53 (63, 132). 
To address this issue we generated a TMD-231 cell line with knockdown of 
Mdm2 in the background of mutant p53 to use as a model for breast to lung metastasis. 
This mutation in p53 occurs as a point mutation, R280K. This mutation resides within the 
DNA binding domain of p53 and renders it incapable of functioning as a transcription 
factor. This mutation allows us to determine if Mdm2 can promote metastasis 
independent of wild-type p53 function. Mdm2 has been implemented in cell growth and 
cell cycle progression not only by inhibiting p53 function, but also through p53-
independent mechanisms. Due to this role of Mdm2, we needed to ascertain if 
knockdown of Mdm2 would affect TMD-231 cell growth and cell cycle progression. 
Knockdown of Mdm2 in SW1990 pancreatic cells has been shown to reduce cellular 
proliferation (132). In contrast, however the growth rates of p53-/- MEFS and p53-/-, 
Mdm2 -/- MEFS are nearly identical (145). Furthermore, expression of Mdm2 splice 
variants incapable of binding p53 can actually inhibit cellular proliferation in vitro (146). 
The knockdown of Mdm2 in our TMD-231 cells did not affect cell growth, providing 
evidence that Mdm2’s role for cell proliferation in cell culture may be cell type specific 
(Figure 35A).  
Mutant p53 can acquire gain of function attributes that aid in cell survival 
advantages, such as increased proliferation, evasion of apoptosis, and chemoresistance. 
These gain of function attributes are seen as the use of shRNA to mutant p53 in MDA-
MB-231 cells results in decreased cell proliferation, reduced invasion in boyden 
chambers, and lower tumor weight in nude mice (147). Important to the scope of this 
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study is the gain of function ability of mutant p53 to enhance tumor metastasis. Mutant 
p53 enhancement of metastatic potential is shown by the observation that p53 knockout 
mice develop tumors at a high frequency, but have a low occurrence of metastasis or 
invasive growth. In contrast, transgenic mice knocked-in with mutant p53 develop highly 
metastatic tumors (148). Furthermore, mutant p53 was found to promote EMT by 
facilitating the function of the key transcriptional regulators of this process, TWIST1 and 
SLUG, and inhibit cell invasion via the inhibition of p63 (130, 149). Since we were 
interested in the role of Mdm2 in metastasis in a p53-independent background, we had to 
be sure that mutant p53 levels were not affected by Mdm2 knockdown. Mdm2 still 
retains the ability to degrade mutant p53 (136), but our results indicated that knockdown 
of Mdm2 had no bearing on mutant p53 protein levels (Figure 34 A&B). If Mdm2 was 
regulating mutant p53 in TMD-231 cells, knockdown of Mdm2 should have resulted in 
an increase of mutant p53 levels. Our result that mutant p53 levels are not altered is in 
agreement with recent findings that suggest mutant p53 cannot interact with Mdm2 in 
cancer cells. (147).  
Comparing our in vitro cell proliferation data to in vivo tumor growth, we note 
that knockdown of Mdm2 does slow in vivo tumor growth (Figure 37A). These differing 
observations hint that Mdm2 may play a role in TMD-231 cells ability to adhere on 
different growth substrates. Mdm2 has been implemented in regulation of cell adhesion 
molecules such as E-cadherin and Syntaxin 6. Thus, loss of Mdm2 may interfere with the 
ability of TMD-231 cells to seed in an in vivo environment. This hypothesis is attractive 
as knockdown of Mdm2 significantly reduces the ability of cells to adhere to fibronectin-
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coated plates (Figure 38). This reasoning would explain why the tumors after an initial 
growth lag were able to eventually seed and grow to the same size as control tumors.  
The ability of the shMdm2 tumors to grow to the same size as control tumors was 
imperative, as we wanted to assure ourselves that the tumor size would have no bearing 
on the ability of the tumors to metastasize. All tumors were harvested when the average 
volume was 600 mm
3
. The average tumor weight for each group was 1.1g (Figure 37 B). 
This allowed us to ensure that the difference seen in metastases was not due to a greater 
tumor weight and volume in the shGFP group, and was solely due to differences in 
Mdm2 expression. This scenario was observed, as knockdown of Mdm2 resulted in 
drastic loss of metastases to the lung. A 60% reduction of lungs metastases was seen in 
the shMdm2 group (Figure 39). Overall the size of the metastases between the two 
groups was similar suggesting that Mdm2 did not have an effect on the ability of the 
tumor cells to grow once they have seeded at a new site. Therefore, Mdm2 may also have 
a role in the intravasation stage of metastasis. The ability of tumor cells to escape into the 
blood stream is dependent on the capacity of the tumor to recruit new vasculature through 
angiogenesis. Mdm2 has been described as having pro-angiogenic properties through its 
regulation of HIF-1α and VEGF. We have shown that Mdm2 can bind HIF-1α and 
enhance VEGF transcription as determined by luciferase activity assays (64). This 
enhancement of HIF-1α transcriptional activity is from an increase in p300 recruitment 
through an Mdm2 dependent process that inhibits hydroxylation of Asn803 in HIF-1α 
both in vivo and in vitro (150). Interestingly, recent work has also shown an Mdm2 
dependent increase of VEGF mRNA stability and translation through Mdm2 binding to 
the AU-rich sequence within the 3' untranslated region of VEGF mRNA (143). Due to 
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Mdm2’s defined role in regulating these pro-angiogenic targets, it was logical to assume 
that our cells and tumors would yield similar experimental results. As expected, 
knockdown of Mdm2 resulted in the loss of HIF-1α and VEGF protein levels in both cell 
culture and tumor lysates (Figure 41 & 42). This loss of angiogenic factors correlates 
with a decrease in vascular endothelial cells in the tumor (Figure 40 A&B), as the 
knockdown of Mdm2 prevented the formation of new vasculature in the tumor. These 
results provide evidence that Mdm2 may enhance tumor metastasis through the 
recruitment of angiogenic factors and allow vascularization of the primary tumor.  
 Metastasis is a multi-step process including tumor cell intravasation, survival in 
circulation, extravasation into a distant organ, angiogenesis and uninhibited cellular 
growth. Due to the role of Mdm2 in numerous cellular processes we could not eliminate 
the possibility that Mdm2 could be functioning in other ways to promote lung metastasis 
than just through regulating pro-angiogenic factors. Recent work by Minn and colleagues 
using MDA-MB-231 cells and transcriptomic analysis identified a set of genes that 
mediates breast cancer metastasis to the lungs (144). Their results showed a subset of 
four genes (SPARC, IL13RA2, VCAM1 and MMP2) whose expression, as determined 
by northern blot was generally seen in aggressive lung-metastatic populations. We show 
that knockdown of Mdm2 results in lower levels of both MMP2 and SPARC (Figure 43). 
Normally SPARC functions as a modulator of the extracellular matrix, but deregulation 
has been linked to an invasive tumor cell phenotype and poor outcome in human 
melanomas. Recent work has shown that SPARC augments tumor growth by stabilizing 
Mdm2 levels through AKT phosphorylation at serine 166. This phosphorylation allows 
Mdm2 to translocate to the nucleus and inactivate p53 in human melanomas (141). This 
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work, along with ours, could support a Mdm2/SPARC network to support tumor growth 
and metastasis.  
 Here we show that Mdm2 is involved in tumor metastasis though multiple p53 
independent functions including a role in tumor cell adherence, regulation of the pro-
angiogenic factors HIF-1α and VEGF, and perpetrating a lung metastatic gene signature 
through increases in the protein levels of SPARC and MMP2. Understanding how Mdm2 
regulates metastasis is important as metastatic disease is usually the terminal step in 
cancer development, so understanding and prevention is critical. Here we present 
evidence that Mdm2 can be a primary component of breast cancer to lung metastasis and 
thus could be a viable clinical target.  
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5. Summary/Future Directions 
Mdm2 serves many diverse functions in a variety of cellular processes and has a 
well-established role in tumorigenesis. Here we have shown that Mdm2, through c-Src 
mediated phosphorylation, can inhibit p53 activity through neddylation while maintaining 
p53 protein levels. We have also confirmed that Mdm2 has a positive role in cancer 
metastasis, thus adding more complex functions to Mdm2 regulation of tumorigenesis. 
Since roles for Mdm2 in cancer are continuing to be identified, a sustained effort to find 
Mdm2 inhibitors for clinical use is urgently needed. Most Mdm2 inhibitors developed 
thus far have focused on inhibiting the p53-Mdm2 interaction in an attempt to re-activate 
p53. The interaction between p53 and Mdm2 involves four residues in p53 (Phe 19, Leu 
22, Trp 23, Leu 26) and a hydrophobic pocket in the N-terminal region of Mdm2. The 
most studied inhibitor has been Nutlin-3a, which inhibits Mdm2-p53 binding by binding 
to the Mdm2 hydrophobic pocket resulting in activation of p53 and leading to cell cycle 
arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice (151). It 
was first assumed that Nutlin would only function in wild-type p53 tumors, but recent 
work has shown that Nutlin can inhibit angiogenesis through inhibition of the 
Mdm2/HIF-1α interaction, independent of p53 (64, 150). Furthermore, it was recently 
demonstrated that Nutlin-3a can upregulate apoptotic genes independent of p53, by 
blocking the p73/Mdm2 interaction (152). These studies show that inhibition of Mdm2 
can still have advantageous results even in absence of wild-type p53 and lends support to 
the developmental ideology for inhibitors that target alternative domains outside of the 
p53-binding region. Inhibition of the Mdm2 RING E3 ligase is an attractive target and 
has been shown to activate p53, which is accomplished through inhibition of p53 
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ubiquitination and neddylation (153). Mdm2 specifies its ligase activity through the 
recruitment of specific E2 enzymes, thus specific inhibitors for each interaction, could be 
an invaluable tool depending on a specific tumor genetic makeup. For tumors with high 
Mdm2/low p53 a Mdm2/Ubc5 inhibitor could be used to inhibit p53 ubiquitination. 
While tumors with high Mdm2/high p53, would benefit from inhibition of Mdm2/Ubc12, 
which would inhibit neddylation, thus personalizing cancer care by specifically targeting 
Mdm2 function. This could be even more advantageous for mutant p53 tumors as Mdm2 
has been shown to ubiquitinate and degrade mutant p53. Interestingly, work has not been 
performed on neddylation of mutant p53 and the downstream signaling consequences. It 
could be envisioned that neddylation of mutant p53 could enhance mutant p53 gain of 
function status. Therefore, inhibition of neddylation, but not ubiquitination could be 
clinically relevant in the treatment of certain cancers.  
Angiogenesis facilitates tumor growth and metastasis. We show here that Mdm2 
has a role in regulating cancer metastasis partly through controlling HIF-1/VEGF levels 
and promoting vascularization of the tumor. Additionally, we also show that c-Src 
phosphorylation of Mdm2 affects the angiogenic pathway through inhibiting the 
expression of p53-mediated transcription of maspin.  
This lead us to hypothesize if c-Src and Mdm2 together could be leading the 
angiogenic switch, since both proteins have been implemented in the positive regulation 
of HIF-1 and VEGF. Since we have shown that c-Src can phosphorylate Mdm2, we  
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Figure 44: c-Src phosphorylation of Mdm2 increases Mdm2/HIF-1 binding 
In vitro GST-pulldown assay using GST-HIF-1 (1-535) and Mdm2. Mdm2 was left 
unphosphorylated or was phosphorylated by c-Src before incubation with GST-HIF-1. 
GST alone was used a negative control. Experiment was performed in duplicate.  
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wondered if this event might enhance the pro-angiogenic phenotype. Through the use of 
in vitro GST-pulldown assays we have data showing that c-Src phosphorylated Mdm2 
binds HIF-1 to a greater degree that unphosphorylated Mdm2, allowing for greater 
transcriptional activity of HIF-1 (Figure 44). Recent work has shown that HIF-1 itself 
is also neddylated, leading to an increase in the protein half-life (154). However the E3 
ligase responsible for this neddylation has yet to be determined. Due to Mdm2 ability to 
bind HIF-1 and function as a neddylating enzyme we wondered if this interaction could 
result in neddylated HIF-1. Through the use of overexpression, and 
immunoprecipitation of HA-nedd8, our data shows that HIF-1 is neddylated in the 
presence Mdm2, but not in the presence of the ligase dead C464S (Figure 45). Thus c-Src 
phosphorylation of Mdm2 results in an increased binding to HIF-1, which enables 
Mdm2 to neddylate HIF-1. This neddylation event would result in an increase of HIF-
1 half-life, allowing for increased HIF-1 transcriptional activity. If this hypothesis is 
correct, then inhibiting c-Src activity should result in the loss of Mdm2 ability to activate 
HIF-1 transcriptional activity. This is shown as treatment with the c-Src inhibitor PP1 
decreases the positive effect of Mdm2 on the HRE-Luc promoter as determined by a 
luciferase assay (Figure 46). These experiments provide evidence that c-Src and Mdm2 
may be collaborating for a pro-angiogenic phenotype, and support future endeavors into 
determining its regulation. 
In conclusion, we have shown novel regulation and activities of the oncogene 
Mdm2. First we have provided evidence that c-Src phosphorylation of Mdm2 can switch 
its E3 ligase activity from ubiquitin to neddylation resulting in stable, but  
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Figure 45: Neddylation of HIF-1 by Mdm2 
H1299 cells, overexpressing HA-Nedd8 plus Mdm2 or C464S, were exposed to hypoxic 
conditions for 16 hr, before the immunoprecipitation of HA-tag. Following 
immunoprecipitation western blot analysis was performed for HIF-1. Bands represent 
neddylated HIF-1. 
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Figure 46: Inhibition of c-Src impairs Mdm2’s ability to enhance HIF-1 
transcriptional activity 
H1299 cells overexpressing HRE-Luc, myc-LacZ, and Mdm2. Cells were treated with 10 
M PP1 for 16 hr before determination of luciferase activity. Y-axis measurements are 
relative luciferase units (RLU). The RLU was calculated from the ratio of luciferase/β-gal 
activity. Error bars represent standard deviation. 
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transcriptionally inactive p53. We have also definitively shown that Mdm2 can enhance 
breast cancer metastasis, independent of p53 status. Taken together, my data provide 
novel insights into important p53-dependent and independent functions of Mdm2 and 
provide potential novel avenues for therapeutic intervention. 
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